[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ff0VJ-pAUnpXRtEHsudcegbXupFxOtpLljgbCrEfC-EA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":60,"rows":67},"SCRI Development Innovations, LLC",[4],178,false,5,4,12281,13,10,[14,17,20,22,25,28,30,32],{"name":15,"count":16},"Breast Cancer",25,{"name":18,"count":19},"Lung Cancer",18,{"name":21,"count":12},"Multiple Myeloma",{"name":23,"count":24},"Metastatic Breast Cancer",9,{"name":26,"count":27},"Non-Small Cell Lung Cancer",6,{"name":29,"count":8},"Prostate Cancer",{"name":31,"count":8},"Non Small Cell Lung Cancer",{"name":33,"count":8},"Colorectal Cancer",[35,40,45,50,55],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT07011576","A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)","2027-01","fruquintinib",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05972135","Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma","2027-08","Teclistamab",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05748834","Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer","2027-11","Tucatinib",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06773910","BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)","2032-05","BMS-986489",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06974786","Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma","2032-11","Elranatamab",[61,62,63,64,65,66],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[68,146,182,205,223,241,259,282,300,325,343,361,379,397,759,906,1009,1076,1118,1164,1190,1212,1230,1444,1528,1588,1667,1719,1774,1836,1891,1937,1967,2004,2045,2071,2097,2130,2156,2190,2222,2251,2285,2312,2349,2371,2393,2415,2441,2472,2494,2516,2541,2577,2599,2623,2645,2673,2700,2725,2749,2781,2803,2821,2839,2863,2881,2899,2917,2935,2953,2971,2994,3012,3030,3053,3071,3093,3120,3138,3161,3179,3202,3220,3238,3256,3274,3292,3310,3328,3346,3368,3390,3408,3426,3444,3468,3486,3504,3522,3544,3567,3585,3603,3626,3652,3670,3688,3706,3724,3742,3760,3778,3796,3818,3839,3863,3881,3899,3917,3940,3958,3982,4004,4025,4048,4066,4084,4105,4123,4141,4159,4177,4265,4322,4368,4414,4440],{"intervention":69,"totalTrials":8,"cells":70},"Lenalidomide",{"EARLY_PHASE1":71,"PHASE1":74,"PHASE2":76,"PHASE3":140,"PHASE4":142,"NA":144},{"trials":72,"activeCount":73},[],0,{"trials":75,"activeCount":73},[],{"trials":77,"activeCount":139,"soonestReadout":58},[78,91,104,116,127],{"nctId":79,"briefTitle":80,"status":81,"phases":82,"primaryCompletion":83,"completion":84,"start":85,"enrollment":86,"conditions":87,"interventions":89},"NCT00837031","Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas","COMPLETED",[63],"2010-04","2012-06","2009-02",72,[88],"Metastatic Pancreatic Cancer",[69,90],"Gemcitabine",{"nctId":92,"briefTitle":93,"status":81,"phases":94,"primaryCompletion":95,"completion":96,"start":97,"enrollment":98,"conditions":99,"interventions":101},"NCT00633594","Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma",[62,63],"2015-04","2016-11","2008-06",39,[100],"Mantle Cell Lymphoma",[102,103,69],"Rituximab","Bortezomib",{"nctId":105,"briefTitle":106,"status":81,"phases":107,"primaryCompletion":108,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":113},"NCT02843074","Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients",[63],"2021-07-27","2021-10-05","2016-09-21",53,[21],[114,69,115],"elotuzumab","Dexamethasone",{"nctId":56,"briefTitle":57,"status":117,"phases":118,"primaryCompletion":58,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":125},"RECRUITING",[63],"2033-04","2025-08-08",100,[123,124],"Multiple Myeloma, Newly Diagnosed","Multiple Myeloma (MM)",[59,126,69],"Daratumumab",{"nctId":128,"briefTitle":129,"status":81,"phases":130,"primaryCompletion":131,"completion":96,"start":132,"enrollment":133,"conditions":134,"interventions":136},"NCT00536341","Fludarabine, Rituximab, and Lenalidomide in Minimally Treated\u002FUntreated Patients With Chronic Lymphocytic Leukemia (CLL)",[62,63],"2013-04","2008-01",64,[135],"Chronic Lymphocytic Leukemia",[137,102,138],"lenalidomide","Fludarabine",1,{"trials":141,"activeCount":73},[],{"trials":143,"activeCount":73},[],{"trials":145,"activeCount":73},[],{"intervention":147,"totalTrials":148,"cells":149},"Doxil",2,{"EARLY_PHASE1":150,"PHASE1":152,"PHASE2":154,"PHASE3":176,"PHASE4":178,"NA":180},{"trials":151,"activeCount":73},[],{"trials":153,"activeCount":73},[],{"trials":155,"activeCount":139,"soonestReadout":48},[156,170],{"nctId":157,"briefTitle":158,"status":159,"phases":160,"primaryCompletion":84,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":168},"NCT01035658","Pazopanib\u002FDoxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma","TERMINATED",[62,63],"2014-03","2010-01",22,[165,166,167],"Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Carcinoma",[169,147],"Pazopanib",{"nctId":46,"briefTitle":47,"status":117,"phases":171,"primaryCompletion":48,"completion":48,"start":172,"enrollment":173,"conditions":174,"interventions":175},[63],"2023-07-24",36,[15],[49,147],{"trials":177,"activeCount":73},[],{"trials":179,"activeCount":73},[],{"trials":181,"activeCount":73},[],{"intervention":44,"totalTrials":139,"cells":183},{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":188,"PHASE3":199,"PHASE4":201,"NA":203},{"trials":185,"activeCount":73},[],{"trials":187,"activeCount":73},[],{"trials":189,"activeCount":139,"soonestReadout":43},[190],{"nctId":41,"briefTitle":42,"status":117,"phases":191,"primaryCompletion":43,"completion":192,"start":193,"enrollment":121,"conditions":194,"interventions":195},[63],"2027-10","2023-10-23",[21],[44,196,197,198],"Talquetamab","Tocilizumab","Oral Dexamethasone",{"trials":200,"activeCount":73},[],{"trials":202,"activeCount":73},[],{"trials":204,"activeCount":73},[],{"intervention":196,"totalTrials":139,"cells":206},{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":217,"PHASE4":219,"NA":221},{"trials":208,"activeCount":73},[],{"trials":210,"activeCount":73},[],{"trials":212,"activeCount":139,"soonestReadout":43},[213],{"nctId":41,"briefTitle":42,"status":117,"phases":214,"primaryCompletion":43,"completion":192,"start":193,"enrollment":121,"conditions":215,"interventions":216},[63],[21],[44,196,197,198],{"trials":218,"activeCount":73},[],{"trials":220,"activeCount":73},[],{"trials":222,"activeCount":73},[],{"intervention":197,"totalTrials":139,"cells":224},{"EARLY_PHASE1":225,"PHASE1":227,"PHASE2":229,"PHASE3":235,"PHASE4":237,"NA":239},{"trials":226,"activeCount":73},[],{"trials":228,"activeCount":73},[],{"trials":230,"activeCount":139,"soonestReadout":43},[231],{"nctId":41,"briefTitle":42,"status":117,"phases":232,"primaryCompletion":43,"completion":192,"start":193,"enrollment":121,"conditions":233,"interventions":234},[63],[21],[44,196,197,198],{"trials":236,"activeCount":73},[],{"trials":238,"activeCount":73},[],{"trials":240,"activeCount":73},[],{"intervention":198,"totalTrials":139,"cells":242},{"EARLY_PHASE1":243,"PHASE1":245,"PHASE2":247,"PHASE3":253,"PHASE4":255,"NA":257},{"trials":244,"activeCount":73},[],{"trials":246,"activeCount":73},[],{"trials":248,"activeCount":139,"soonestReadout":43},[249],{"nctId":41,"briefTitle":42,"status":117,"phases":250,"primaryCompletion":43,"completion":192,"start":193,"enrollment":121,"conditions":251,"interventions":252},[63],[21],[44,196,197,198],{"trials":254,"activeCount":73},[],{"trials":256,"activeCount":73},[],{"trials":258,"activeCount":73},[],{"intervention":54,"totalTrials":139,"cells":260},{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":276,"PHASE4":278,"NA":280},{"trials":262,"activeCount":73},[],{"trials":264,"activeCount":73},[],{"trials":266,"activeCount":139,"soonestReadout":53},[267],{"nctId":51,"briefTitle":52,"status":117,"phases":268,"primaryCompletion":53,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":274},[63],"2032-09","2025-03-11",250,[273],"Limited Stage Small Cell Lung Cancer",[54,275],"Durvalumab",{"trials":277,"activeCount":73},[],{"trials":279,"activeCount":73},[],{"trials":281,"activeCount":73},[],{"intervention":275,"totalTrials":139,"cells":283},{"EARLY_PHASE1":284,"PHASE1":286,"PHASE2":288,"PHASE3":294,"PHASE4":296,"NA":298},{"trials":285,"activeCount":73},[],{"trials":287,"activeCount":73},[],{"trials":289,"activeCount":139,"soonestReadout":53},[290],{"nctId":51,"briefTitle":52,"status":117,"phases":291,"primaryCompletion":53,"completion":269,"start":270,"enrollment":271,"conditions":292,"interventions":293},[63],[273],[54,275],{"trials":295,"activeCount":73},[],{"trials":297,"activeCount":73},[],{"trials":299,"activeCount":73},[],{"intervention":39,"totalTrials":139,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":319,"PHASE4":321,"NA":323},{"trials":303,"activeCount":73},[],{"trials":305,"activeCount":73},[],{"trials":307,"activeCount":139,"soonestReadout":38},[308],{"nctId":36,"briefTitle":37,"status":117,"phases":309,"primaryCompletion":38,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":317},[63],"2027-06","2025-09-29",60,[314,315,33,316],"Colon Cancer","Rectal Cancer","Colorectal Cancer (CRC)",[39,318],"FOLFIRI",{"trials":320,"activeCount":73},[],{"trials":322,"activeCount":73},[],{"trials":324,"activeCount":73},[],{"intervention":318,"totalTrials":139,"cells":326},{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":337,"PHASE4":339,"NA":341},{"trials":328,"activeCount":73},[],{"trials":330,"activeCount":73},[],{"trials":332,"activeCount":139,"soonestReadout":38},[333],{"nctId":36,"briefTitle":37,"status":117,"phases":334,"primaryCompletion":38,"completion":310,"start":311,"enrollment":312,"conditions":335,"interventions":336},[63],[314,315,33,316],[39,318],{"trials":338,"activeCount":73},[],{"trials":340,"activeCount":73},[],{"trials":342,"activeCount":73},[],{"intervention":49,"totalTrials":139,"cells":344},{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":355,"PHASE4":357,"NA":359},{"trials":346,"activeCount":73},[],{"trials":348,"activeCount":73},[],{"trials":350,"activeCount":139,"soonestReadout":48},[351],{"nctId":46,"briefTitle":47,"status":117,"phases":352,"primaryCompletion":48,"completion":48,"start":172,"enrollment":173,"conditions":353,"interventions":354},[63],[15],[49,147],{"trials":356,"activeCount":73},[],{"trials":358,"activeCount":73},[],{"trials":360,"activeCount":73},[],{"intervention":59,"totalTrials":139,"cells":362},{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":373,"PHASE4":375,"NA":377},{"trials":364,"activeCount":73},[],{"trials":366,"activeCount":73},[],{"trials":368,"activeCount":139,"soonestReadout":58},[369],{"nctId":56,"briefTitle":57,"status":117,"phases":370,"primaryCompletion":58,"completion":119,"start":120,"enrollment":121,"conditions":371,"interventions":372},[63],[123,124],[59,126,69],{"trials":374,"activeCount":73},[],{"trials":376,"activeCount":73},[],{"trials":378,"activeCount":73},[],{"intervention":126,"totalTrials":139,"cells":380},{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":391,"PHASE4":393,"NA":395},{"trials":382,"activeCount":73},[],{"trials":384,"activeCount":73},[],{"trials":386,"activeCount":139,"soonestReadout":58},[387],{"nctId":56,"briefTitle":57,"status":117,"phases":388,"primaryCompletion":58,"completion":119,"start":120,"enrollment":121,"conditions":389,"interventions":390},[63],[123,124],[59,126,69],{"trials":392,"activeCount":73},[],{"trials":394,"activeCount":73},[],{"trials":396,"activeCount":73},[],{"intervention":398,"totalTrials":399,"cells":400},"Carboplatin",34,{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":416,"PHASE3":735,"PHASE4":755,"NA":757},{"trials":402,"activeCount":73},[],{"trials":404,"activeCount":73},[405],{"nctId":406,"briefTitle":407,"status":81,"phases":408,"primaryCompletion":409,"completion":410,"start":411,"enrollment":19,"conditions":412,"interventions":414},"NCT00193583","Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and\u002For Advanced Solid Tumors",[62],"2004-05","2005-05","2003-05",[413],"Cancer",[415,398],"Topotecan",{"trials":417,"activeCount":73},[418,431,441,452,462,475,486,496,506,516,523,534,547,556,565,577,589,601,611,620,632,641,651,660,671,681,690,699,707,716,725],{"nctId":419,"briefTitle":420,"status":81,"phases":421,"primaryCompletion":422,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":428},"NCT01042288","Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC",[63],"2014-12","2015-07","2010-06",70,[427],"Non-Small-Cell Lung Cancer",[398,429,430],"Pemetrexed","Panitumumab",{"nctId":432,"briefTitle":433,"status":81,"phases":434,"primaryCompletion":435,"completion":436,"start":437,"enrollment":271,"conditions":438,"interventions":439},"NCT00193310","Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer",[63],"2003-11","2009-01","2000-11",[18],[440,398],"Paclitaxel",{"nctId":442,"briefTitle":443,"status":81,"phases":444,"primaryCompletion":445,"completion":446,"start":447,"enrollment":448,"conditions":449,"interventions":450},"NCT00193427","Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer",[63],"2008-11","2008-12","2004-04",75,[18],[451,90,398],"Docetaxel",{"nctId":453,"briefTitle":454,"status":81,"phases":455,"primaryCompletion":456,"completion":457,"start":458,"enrollment":121,"conditions":459,"interventions":460},"NCT00193193","Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma",[63],"2003-12","2007-02","2000-08",[29],[440,461,398],"Estramustine",{"nctId":463,"briefTitle":464,"status":81,"phases":465,"primaryCompletion":466,"completion":436,"start":467,"enrollment":468,"conditions":469,"interventions":471},"NCT00308529","Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer",[63],"2007-04","2006-03",55,[470,18],"Carcinoma, Small Cell Lung",[472,473,474],"irinotecan","carboplatin","bevacizumab",{"nctId":476,"briefTitle":477,"status":81,"phases":478,"primaryCompletion":479,"completion":480,"start":481,"enrollment":482,"conditions":483,"interventions":484},"NCT00892710","Trial of Poor Performance Status Patients (ToPPS)",[63],"2014-07","2015-05","2009-06",172,[31],[429,485,398],"Bevacizumab",{"nctId":487,"briefTitle":488,"status":81,"phases":489,"primaryCompletion":490,"completion":491,"start":492,"enrollment":312,"conditions":493,"interventions":494},"NCT00193375","Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer",[63],"2008-04","2008-05","2003-08",[18],[495,398,485],"Irinotecan",{"nctId":497,"briefTitle":498,"status":81,"phases":499,"primaryCompletion":500,"completion":500,"start":501,"enrollment":121,"conditions":502,"interventions":504},"NCT00193531","Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma",[63],"2007-01","1998-12",[503],"Neuroendocrine Carcinoma",[440,398,505],"Etoposide",{"nctId":507,"briefTitle":508,"status":81,"phases":509,"primaryCompletion":510,"completion":511,"start":85,"enrollment":312,"conditions":512,"interventions":513},"NCT00821886","Neoadjuvant Ixabepilone\u002FCarboplatin\u002FTrastuzumab in HER2-Positive Locally Advanced Breast Cancer",[63],"2011-07","2014-10",[15],[514,515,398],"Ixabepilone","Trastuzumab",{"nctId":517,"briefTitle":518,"status":159,"phases":519,"primaryCompletion":436,"completion":436,"start":520,"enrollment":8,"conditions":521,"interventions":522},"NCT00402883","Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer",[63],"2006-11",[18],[485,429,473],{"nctId":524,"briefTitle":525,"status":81,"phases":526,"primaryCompletion":527,"completion":528,"start":97,"enrollment":529,"conditions":530,"interventions":532},"NCT00695292","Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer",[63],"2011-06","2012-09",37,[531],"Small Cell Lung Cancer",[472,398,533],"sunitinib",{"nctId":535,"briefTitle":536,"status":81,"phases":537,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":544},"NCT01076504","A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer",[63],"2012-03","2015-03","2009-12",81,[543],"Extensive-Stage Small Cell Lung Cancer",[545,398,546],"Amrubicin","Pegfilgrastim",{"nctId":548,"briefTitle":549,"status":159,"phases":550,"primaryCompletion":551,"completion":552,"start":553,"enrollment":9,"conditions":554,"interventions":555},"NCT00960297","Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC",[63],"2012-11","2013-05","2009-08",[26],[398,440,485],{"nctId":557,"briefTitle":558,"status":81,"phases":559,"primaryCompletion":560,"completion":561,"start":435,"enrollment":562,"conditions":563,"interventions":564},"NCT00193076","Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer",[63],"2006-05","2008-10",96,[15],[90,398,515],{"nctId":566,"briefTitle":567,"status":81,"phases":568,"primaryCompletion":569,"completion":570,"start":571,"enrollment":572,"conditions":573,"interventions":575},"NCT00193141","Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer",[63],"2004-10","2007-07","1999-10",200,[574],"Esophagus Cancer",[440,398,576],"5-Fluorouracil",{"nctId":578,"briefTitle":579,"status":81,"phases":580,"primaryCompletion":581,"completion":582,"start":583,"enrollment":312,"conditions":584,"interventions":586},"NCT00360360","Paclitaxel\u002FCarboplatin Plus Bevacizumab\u002FErlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site",[63],"2008-02","2009-03","2006-07",[585],"Neoplasm, Unknown Primary",[587,473,474,588],"paclitaxel","erlotinib",{"nctId":590,"briefTitle":591,"status":81,"phases":592,"primaryCompletion":593,"completion":593,"start":594,"enrollment":595,"conditions":596,"interventions":598},"NCT00193505","Ifosfamide\u002FCarboplatin\u002FEtoposide\u002FRituxan Followed by Zevalin in Relapsed\u002FRefractory Intermediate Grade B-Cell Lymphoma",[63],"2005-08","2003-10",40,[597],"Non-Hodgkins Lymphoma",[599,398,505,102,600],"Ifosfamide","90Y Zevalin",{"nctId":602,"briefTitle":603,"status":81,"phases":604,"primaryCompletion":605,"completion":606,"start":467,"enrollment":607,"conditions":608,"interventions":610},"NCT00305942","Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer",[63],"2009-04","2009-11",61,[609],"Carcinoma, Small Cell",[415,473],{"nctId":612,"briefTitle":613,"status":81,"phases":614,"primaryCompletion":615,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":619},"NCT00894504","Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer",[63],"2014-09","2010-02",71,[23],[430,398,90],{"nctId":621,"briefTitle":622,"status":81,"phases":623,"primaryCompletion":624,"completion":625,"start":457,"enrollment":626,"conditions":627,"interventions":629},"NCT00393068","Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer",[63],"2009-09","2011-08",62,[628],"Esophageal Cancer",[630,485,440,398,631],"Erlotinib","5-FU",{"nctId":633,"briefTitle":634,"status":81,"phases":635,"primaryCompletion":636,"completion":615,"start":481,"enrollment":637,"conditions":638,"interventions":639},"NCT00887575","Neoadjuvant Sunitinib With Paclitaxel\u002FCarboplatin in Patients With Triple-Negative Breast Cancer",[62,63],"2013-07",54,[15],[440,398,640],"Sunitinib",{"nctId":642,"briefTitle":643,"status":81,"phases":644,"primaryCompletion":645,"completion":646,"start":616,"enrollment":425,"conditions":647,"interventions":649},"NCT01014351","Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma",[63],"2012-02","2013-08",[648],"Metastatic Melanoma",[440,398,650],"Everolimus",{"nctId":652,"briefTitle":653,"status":81,"phases":654,"primaryCompletion":655,"completion":436,"start":656,"enrollment":657,"conditions":658,"interventions":659},"NCT00294931","Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer",[63],"2007-05","2006-02",50,[470],[472,473,474],{"nctId":661,"briefTitle":662,"status":81,"phases":663,"primaryCompletion":664,"completion":665,"start":666,"enrollment":667,"conditions":668,"interventions":669},"NCT00390611","Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer",[63],"2012-07","2014-04","2006-10",85,[165],[670,440,398],"Sorafenib",{"nctId":672,"briefTitle":673,"status":81,"phases":674,"primaryCompletion":675,"completion":676,"start":677,"enrollment":657,"conditions":678,"interventions":680},"NCT00193297","Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma",[63],"2005-06","2006-06","2002-02",[679],"Ovary Cancer",[415,440,398],{"nctId":682,"briefTitle":683,"status":81,"phases":684,"primaryCompletion":656,"completion":436,"start":594,"enrollment":657,"conditions":685,"interventions":687},"NCT00193284","Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer",[63],[686],"Head and Neck Cancer",[688,451,398,689],"Gefitinib","Fluorouracil",{"nctId":691,"briefTitle":692,"status":81,"phases":693,"primaryCompletion":694,"completion":694,"start":695,"enrollment":312,"conditions":696,"interventions":697},"NCT00193349","Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer",[63],"2007-12","2002-09",[18],[698,495,398],"Imatinib",{"nctId":700,"briefTitle":701,"status":81,"phases":702,"primaryCompletion":616,"completion":528,"start":703,"enrollment":704,"conditions":705,"interventions":706},"NCT00456261","First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC",[63],"2007-03",110,[18],[429,90,485,398],{"nctId":708,"briefTitle":709,"status":81,"phases":710,"primaryCompletion":711,"completion":528,"start":712,"enrollment":713,"conditions":714,"interventions":715},"NCT00741988","Ixabepilone and Carboplatin +\u002F- Bevacizumab in Advanced Non-Small-Cell Lung Cancer",[63],"2010-09","2008-09",82,[26],[514,398,485],{"nctId":717,"briefTitle":718,"status":81,"phases":719,"primaryCompletion":720,"completion":721,"start":481,"enrollment":722,"conditions":723,"interventions":724},"NCT00906282","Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer",[63],"2015-08","2015-09",46,[31],[429,398],{"nctId":726,"briefTitle":727,"status":81,"phases":728,"primaryCompletion":551,"completion":729,"start":730,"enrollment":731,"conditions":732,"interventions":734},"NCT00737243","Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site",[63],"2012-12","2008-08",289,[733],"Carcinoma",[440,398,485,630],{"trials":736,"activeCount":73},[737,746],{"nctId":738,"briefTitle":739,"status":81,"phases":740,"primaryCompletion":675,"completion":741,"start":742,"enrollment":572,"conditions":743,"interventions":744},"NCT00193362","Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer",[64],"2007-09","2004-06",[18],[440,398,90,745],"Vinorelbine",{"nctId":747,"briefTitle":748,"status":81,"phases":749,"primaryCompletion":712,"completion":481,"start":750,"enrollment":751,"conditions":752,"interventions":754},"NCT00193596","Gemcitabine\u002FIrinotecan\u002FZD1839 vs Paclitaxel\u002FCarboplatin\u002FEtoposide\u002FZD1839 in Carcinoma of Unknown Primary Site",[64],"2003-09",198,[753],"Neoplasms, Unknown Primary",[505,90,495,440,398],{"trials":756,"activeCount":73},[],{"trials":758,"activeCount":73},[],{"intervention":451,"totalTrials":760,"cells":761},17,{"EARLY_PHASE1":762,"PHASE1":764,"PHASE2":774,"PHASE3":891,"PHASE4":902,"NA":904},{"trials":763,"activeCount":73},[],{"trials":765,"activeCount":73},[766],{"nctId":767,"briefTitle":768,"status":81,"phases":769,"primaryCompletion":770,"completion":436,"start":677,"enrollment":771,"conditions":772,"interventions":773},"NCT00193570","Topotecan in Combination With Docetaxel in Refractory and\u002For Advanced Solid Tumors",[62],"2004-08",20,[413],[415,451],{"trials":775,"activeCount":73},[776,785,789,796,803,812,820,826,834,845,854,863,867,874,882],{"nctId":777,"briefTitle":778,"status":81,"phases":779,"primaryCompletion":780,"completion":582,"start":781,"enrollment":704,"conditions":782,"interventions":783},"NCT00193050","Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer",[63],"2008-03","2001-11",[15],[90,784,451],"Epirubicin",{"nctId":442,"briefTitle":443,"status":81,"phases":786,"primaryCompletion":445,"completion":446,"start":447,"enrollment":448,"conditions":787,"interventions":788},[63],[18],[451,90,398],{"nctId":790,"briefTitle":791,"status":81,"phases":792,"primaryCompletion":793,"completion":457,"start":409,"enrollment":657,"conditions":794,"interventions":795},"NCT00193232","Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer",[63],"2005-10",[29],[451,103],{"nctId":797,"briefTitle":798,"status":81,"phases":799,"primaryCompletion":655,"completion":655,"start":770,"enrollment":800,"conditions":801,"interventions":802},"NCT00193271","Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer",[63],30,[29],[451,461],{"nctId":804,"briefTitle":805,"status":81,"phases":806,"primaryCompletion":446,"completion":606,"start":807,"enrollment":808,"conditions":809,"interventions":810},"NCT00193037","Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer",[63],"2001-02",102,[15],[811,451],"Liposomal Doxorubicin",{"nctId":813,"briefTitle":814,"status":81,"phases":815,"primaryCompletion":816,"completion":624,"start":817,"enrollment":312,"conditions":818,"interventions":819},"NCT00193089","Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer",[63],"2005-04","2001-04",[15],[451,745,515],{"nctId":821,"briefTitle":822,"status":81,"phases":823,"primaryCompletion":491,"completion":436,"start":410,"enrollment":529,"conditions":824,"interventions":825},"NCT00193180","Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer",[63],[15],[698,451],{"nctId":827,"briefTitle":828,"status":159,"phases":829,"primaryCompletion":594,"completion":569,"start":830,"enrollment":831,"conditions":832,"interventions":833},"NCT00193024","Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer",[63],"2001-09",90,[15],[451,784],{"nctId":835,"briefTitle":836,"status":81,"phases":837,"primaryCompletion":615,"completion":838,"start":84,"enrollment":839,"conditions":840,"interventions":842},"NCT01527487","Trial of Eribulin\u002FCyclophosphamide or Docetaxel\u002FCyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer",[63],"2016-07",76,[841],"HER2 Negative Breast Cancer",[843,844,451],"Eribulin","Cyclophosphamide",{"nctId":846,"briefTitle":847,"status":81,"phases":848,"primaryCompletion":581,"completion":436,"start":447,"enrollment":849,"conditions":850,"interventions":851},"NCT00193128","Preoperative Therapy With Oxaliplatin\u002FDocetaxel\u002FCapecitabine and Radiation in Resectable Esophagus Cancer",[62,63],59,[574],[852,451,853],"Oxaliplatin","Capecitabine",{"nctId":855,"briefTitle":856,"status":81,"phases":857,"primaryCompletion":675,"completion":436,"start":858,"enrollment":859,"conditions":860,"interventions":861},"NCT00193115","Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer",[63],"2004-03",32,[15],[451,862,844],"Doxorubicin",{"nctId":682,"briefTitle":683,"status":81,"phases":864,"primaryCompletion":656,"completion":436,"start":594,"enrollment":657,"conditions":865,"interventions":866},[63],[686],[688,451,398,689],{"nctId":868,"briefTitle":869,"status":81,"phases":870,"primaryCompletion":793,"completion":436,"start":437,"enrollment":871,"conditions":872,"interventions":873},"NCT00193245","Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer",[63],80,[18],[415,451],{"nctId":875,"briefTitle":876,"status":81,"phases":877,"primaryCompletion":560,"completion":436,"start":878,"enrollment":879,"conditions":880,"interventions":881},"NCT00193323","Weekly Docetaxel Versus Weekly Docetaxel\u002FGemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients",[63],"2001-08",346,[18],[451,90],{"nctId":883,"briefTitle":884,"status":81,"phases":885,"primaryCompletion":85,"completion":540,"start":886,"enrollment":887,"conditions":888,"interventions":889},"NCT00193453","Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer",[63],"2005-07",69,[18],[90,451,890],"Cetuximab",{"trials":892,"activeCount":73},[893],{"nctId":894,"briefTitle":895,"status":81,"phases":896,"primaryCompletion":770,"completion":770,"start":897,"enrollment":898,"conditions":899,"interventions":900},"NCT00193011","Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer",[64],"2002-03",150,[15],[451,844,901,576],"Methotrexate",{"trials":903,"activeCount":73},[],{"trials":905,"activeCount":73},[],{"intervention":90,"totalTrials":907,"cells":908},15,{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":913,"PHASE3":995,"PHASE4":1005,"NA":1007},{"trials":910,"activeCount":73},[],{"trials":912,"activeCount":73},[],{"trials":914,"activeCount":73},[915,919,923,929,933,937,941,952,961,965,969,978,991],{"nctId":777,"briefTitle":778,"status":81,"phases":916,"primaryCompletion":780,"completion":582,"start":781,"enrollment":704,"conditions":917,"interventions":918},[63],[15],[90,784,451],{"nctId":442,"briefTitle":443,"status":81,"phases":920,"primaryCompletion":445,"completion":446,"start":447,"enrollment":448,"conditions":921,"interventions":922},[63],[18],[451,90,398],{"nctId":924,"briefTitle":925,"status":81,"phases":926,"primaryCompletion":446,"completion":553,"start":410,"enrollment":86,"conditions":927,"interventions":928},"NCT00193414","Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer",[63],[18],[429,90],{"nctId":79,"briefTitle":80,"status":81,"phases":930,"primaryCompletion":83,"completion":84,"start":85,"enrollment":86,"conditions":931,"interventions":932},[63],[88],[69,90],{"nctId":557,"briefTitle":558,"status":81,"phases":934,"primaryCompletion":560,"completion":561,"start":435,"enrollment":562,"conditions":935,"interventions":936},[63],[15],[90,398,515],{"nctId":612,"briefTitle":613,"status":81,"phases":938,"primaryCompletion":615,"completion":615,"start":616,"enrollment":617,"conditions":939,"interventions":940},[63],[23],[430,398,90],{"nctId":942,"briefTitle":943,"status":81,"phases":944,"primaryCompletion":446,"completion":945,"start":946,"enrollment":947,"conditions":948,"interventions":950},"NCT00540579","CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas",[62,63],"2011-01","2007-11",23,[949],"Pancreatic Cancer",[951,90],"Pomalidomide",{"nctId":953,"briefTitle":954,"status":81,"phases":955,"primaryCompletion":956,"completion":553,"start":957,"enrollment":958,"conditions":959,"interventions":960},"NCT00193063","Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer",[63],"2009-05","2001-07",41,[15],[515,90],{"nctId":700,"briefTitle":701,"status":81,"phases":962,"primaryCompletion":616,"completion":528,"start":703,"enrollment":704,"conditions":963,"interventions":964},[63],[18],[429,90,485,398],{"nctId":875,"briefTitle":876,"status":81,"phases":966,"primaryCompletion":560,"completion":436,"start":878,"enrollment":879,"conditions":967,"interventions":968},[63],[18],[451,90],{"nctId":970,"briefTitle":971,"status":81,"phases":972,"primaryCompletion":561,"completion":956,"start":973,"enrollment":974,"conditions":975,"interventions":976},"NCT00193206","Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer",[63],"2005-09",123,[15],[90,784,977],"Albumin-bound Paclitaxel",{"nctId":979,"briefTitle":980,"status":159,"phases":981,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":985,"interventions":989},"NCT02887248","Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma",[63],"2020-05-01","2017-01-12",3,[986,987,988],"Urothelial Carcinoma","Bladder Cancer","Transitional Cell Carcinoma",[990,90],"nab-paclitaxel",{"nctId":883,"briefTitle":884,"status":81,"phases":992,"primaryCompletion":85,"completion":540,"start":886,"enrollment":887,"conditions":993,"interventions":994},[63],[18],[90,451,890],{"trials":996,"activeCount":73},[997,1001],{"nctId":738,"briefTitle":739,"status":81,"phases":998,"primaryCompletion":675,"completion":741,"start":742,"enrollment":572,"conditions":999,"interventions":1000},[64],[18],[440,398,90,745],{"nctId":747,"briefTitle":748,"status":81,"phases":1002,"primaryCompletion":712,"completion":481,"start":750,"enrollment":751,"conditions":1003,"interventions":1004},[64],[753],[505,90,495,440,398],{"trials":1006,"activeCount":73},[],{"trials":1008,"activeCount":73},[],{"intervention":576,"totalTrials":1010,"cells":1011},7,{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1066,"PHASE4":1072,"NA":1074},{"trials":1013,"activeCount":73},[],{"trials":1015,"activeCount":73},[],{"trials":1017,"activeCount":73},[1018,1027,1039,1047,1051,1059],{"nctId":1019,"briefTitle":1020,"status":81,"phases":1021,"primaryCompletion":97,"completion":1022,"start":886,"enrollment":173,"conditions":1023,"interventions":1024},"NCT00193219","Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer",[63],"2010-07",[314],[485,890,1025,1026,852],"5-fluorouracil","Leucovorin",{"nctId":1028,"briefTitle":1029,"status":159,"phases":1030,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1037},"NCT01769508","Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer",[63],"2014-02","2015-02","2013-02",12,[1036],"HER2 Positive Esophagogastric Cancer",[576,852,1038],"Lapatinib",{"nctId":1040,"briefTitle":1041,"status":81,"phases":1042,"primaryCompletion":423,"completion":423,"start":1043,"enrollment":425,"conditions":1044,"interventions":1045},"NCT01490866","A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)",[63],"2012-01",[33],[1046,485,576,576,1026,852],"Axitinib",{"nctId":566,"briefTitle":567,"status":81,"phases":1048,"primaryCompletion":569,"completion":570,"start":571,"enrollment":572,"conditions":1049,"interventions":1050},[63],[574],[440,398,576],{"nctId":1052,"briefTitle":1053,"status":81,"phases":1054,"primaryCompletion":605,"completion":645,"start":467,"enrollment":1055,"conditions":1056,"interventions":1058},"NCT00308516","5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II\u002FIII Rectal Cancer",[63],66,[315,1057,33],"Cancer of the Rectum",[576,485,852,1026],{"nctId":1060,"briefTitle":1061,"status":81,"phases":1062,"primaryCompletion":161,"completion":161,"start":1063,"enrollment":907,"conditions":1064,"interventions":1065},"NCT01226719","FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only",[63],"2010-12",[33],[430,852,495,1026,576],{"trials":1067,"activeCount":73},[1068],{"nctId":894,"briefTitle":895,"status":81,"phases":1069,"primaryCompletion":770,"completion":770,"start":897,"enrollment":898,"conditions":1070,"interventions":1071},[64],[15],[451,844,901,576],{"trials":1073,"activeCount":73},[],{"trials":1075,"activeCount":73},[],{"intervention":495,"totalTrials":1010,"cells":1077},{"EARLY_PHASE1":1078,"PHASE1":1080,"PHASE2":1082,"PHASE3":1108,"PHASE4":1114,"NA":1116},{"trials":1079,"activeCount":73},[],{"trials":1081,"activeCount":73},[],{"trials":1083,"activeCount":73},[1084,1088,1092,1096,1100,1104],{"nctId":463,"briefTitle":464,"status":81,"phases":1085,"primaryCompletion":466,"completion":436,"start":467,"enrollment":468,"conditions":1086,"interventions":1087},[63],[470,18],[472,473,474],{"nctId":487,"briefTitle":488,"status":81,"phases":1089,"primaryCompletion":490,"completion":491,"start":492,"enrollment":312,"conditions":1090,"interventions":1091},[63],[18],[495,398,485],{"nctId":524,"briefTitle":525,"status":81,"phases":1093,"primaryCompletion":527,"completion":528,"start":97,"enrollment":529,"conditions":1094,"interventions":1095},[63],[531],[472,398,533],{"nctId":652,"briefTitle":653,"status":81,"phases":1097,"primaryCompletion":655,"completion":436,"start":656,"enrollment":657,"conditions":1098,"interventions":1099},[63],[470],[472,473,474],{"nctId":691,"briefTitle":692,"status":81,"phases":1101,"primaryCompletion":694,"completion":694,"start":695,"enrollment":312,"conditions":1102,"interventions":1103},[63],[18],[698,495,398],{"nctId":1060,"briefTitle":1061,"status":81,"phases":1105,"primaryCompletion":161,"completion":161,"start":1063,"enrollment":907,"conditions":1106,"interventions":1107},[63],[33],[430,852,495,1026,576],{"trials":1109,"activeCount":73},[1110],{"nctId":747,"briefTitle":748,"status":81,"phases":1111,"primaryCompletion":712,"completion":481,"start":750,"enrollment":751,"conditions":1112,"interventions":1113},[64],[753],[505,90,495,440,398],{"trials":1115,"activeCount":73},[],{"trials":1117,"activeCount":73},[],{"intervention":514,"totalTrials":8,"cells":1119},{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1150,"PHASE4":1160,"NA":1162},{"trials":1121,"activeCount":73},[],{"trials":1123,"activeCount":73},[],{"trials":1125,"activeCount":73},[1126,1130,1139,1143],{"nctId":507,"briefTitle":508,"status":81,"phases":1127,"primaryCompletion":510,"completion":511,"start":85,"enrollment":312,"conditions":1128,"interventions":1129},[63],[15],[514,515,398],{"nctId":1131,"briefTitle":1132,"status":81,"phases":1133,"primaryCompletion":1134,"completion":1135,"start":582,"enrollment":1136,"conditions":1137,"interventions":1138},"NCT00825734","Phase I\u002FII Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer",[62,63],"2013-06","2014-08",83,[23],[670,514],{"nctId":708,"briefTitle":709,"status":81,"phases":1140,"primaryCompletion":711,"completion":528,"start":712,"enrollment":713,"conditions":1141,"interventions":1142},[63],[26],[514,398,485],{"nctId":1144,"briefTitle":1145,"status":81,"phases":1146,"primaryCompletion":479,"completion":511,"start":605,"enrollment":1147,"conditions":1148,"interventions":1149},"NCT00866905","Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer",[63],168,[15],[514,844],{"trials":1151,"activeCount":73},[1152],{"nctId":1153,"briefTitle":1154,"status":81,"phases":1155,"primaryCompletion":1156,"completion":96,"start":446,"enrollment":1157,"conditions":1158,"interventions":1159},"NCT00789581","A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer",[64],"2015-12",614,[15],[862,844,514,440],{"trials":1161,"activeCount":73},[],{"trials":1163,"activeCount":73},[],{"intervention":505,"totalTrials":984,"cells":1165},{"EARLY_PHASE1":1166,"PHASE1":1168,"PHASE2":1170,"PHASE3":1180,"PHASE4":1186,"NA":1188},{"trials":1167,"activeCount":73},[],{"trials":1169,"activeCount":73},[],{"trials":1171,"activeCount":73},[1172,1176],{"nctId":497,"briefTitle":498,"status":81,"phases":1173,"primaryCompletion":500,"completion":500,"start":501,"enrollment":121,"conditions":1174,"interventions":1175},[63],[503],[440,398,505],{"nctId":590,"briefTitle":591,"status":81,"phases":1177,"primaryCompletion":593,"completion":593,"start":594,"enrollment":595,"conditions":1178,"interventions":1179},[63],[597],[599,398,505,102,600],{"trials":1181,"activeCount":73},[1182],{"nctId":747,"briefTitle":748,"status":81,"phases":1183,"primaryCompletion":712,"completion":481,"start":750,"enrollment":751,"conditions":1184,"interventions":1185},[64],[753],[505,90,495,440,398],{"trials":1187,"activeCount":73},[],{"trials":1189,"activeCount":73},[],{"intervention":745,"totalTrials":148,"cells":1191},{"EARLY_PHASE1":1192,"PHASE1":1194,"PHASE2":1196,"PHASE3":1202,"PHASE4":1208,"NA":1210},{"trials":1193,"activeCount":73},[],{"trials":1195,"activeCount":73},[],{"trials":1197,"activeCount":73},[1198],{"nctId":813,"briefTitle":814,"status":81,"phases":1199,"primaryCompletion":816,"completion":624,"start":817,"enrollment":312,"conditions":1200,"interventions":1201},[63],[15],[451,745,515],{"trials":1203,"activeCount":73},[1204],{"nctId":738,"briefTitle":739,"status":81,"phases":1205,"primaryCompletion":675,"completion":741,"start":742,"enrollment":572,"conditions":1206,"interventions":1207},[64],[18],[440,398,90,745],{"trials":1209,"activeCount":73},[],{"trials":1211,"activeCount":73},[],{"intervention":901,"totalTrials":139,"cells":1213},{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1220,"PHASE4":1226,"NA":1228},{"trials":1215,"activeCount":73},[],{"trials":1217,"activeCount":73},[],{"trials":1219,"activeCount":73},[],{"trials":1221,"activeCount":73},[1222],{"nctId":894,"briefTitle":895,"status":81,"phases":1223,"primaryCompletion":770,"completion":770,"start":897,"enrollment":898,"conditions":1224,"interventions":1225},[64],[15],[451,844,901,576],{"trials":1227,"activeCount":73},[],{"trials":1229,"activeCount":73},[],{"intervention":485,"totalTrials":800,"cells":1231},{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1250,"PHASE3":1438,"PHASE4":1440,"NA":1442},{"trials":1233,"activeCount":73},[],{"trials":1235,"activeCount":73},[1236],{"nctId":1237,"briefTitle":1238,"status":81,"phases":1239,"primaryCompletion":1240,"completion":1241,"start":1242,"enrollment":1243,"conditions":1244,"interventions":1248},"NCT02386826","INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme",[62],"2021-07-31","2023-08-23","2015-09-22",65,[1245,1246,33,1247],"Glioblastoma Multiforme","Gliosarcoma","Renal Cell Carcinoma",[1249,474],"INC280",{"trials":1251,"activeCount":73},[1252,1258,1262,1270,1274,1278,1282,1290,1299,1308,1318,1328,1337,1345,1349,1358,1362,1370,1374,1378,1388,1395,1399,1408,1412,1422,1426,1430,1434],{"nctId":1253,"briefTitle":1254,"status":81,"phases":1255,"primaryCompletion":973,"completion":436,"start":447,"enrollment":657,"conditions":1256,"interventions":1257},"NCT00193622","Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site",[63],[753],[485,630],{"nctId":1019,"briefTitle":1020,"status":81,"phases":1259,"primaryCompletion":97,"completion":1022,"start":886,"enrollment":173,"conditions":1260,"interventions":1261},[63],[314],[485,890,1025,1026,852],{"nctId":1263,"briefTitle":1264,"status":81,"phases":1265,"primaryCompletion":730,"completion":1266,"start":1267,"enrollment":312,"conditions":1268,"interventions":1269},"NCT00392704","Treatment of Head & Neck Cancer With Chemotherapy and Radiation",[63],"2012-05","2006-12",[686],[485,630,440,631],{"nctId":463,"briefTitle":464,"status":81,"phases":1271,"primaryCompletion":466,"completion":436,"start":467,"enrollment":468,"conditions":1272,"interventions":1273},[63],[470,18],[472,473,474],{"nctId":476,"briefTitle":477,"status":81,"phases":1275,"primaryCompletion":479,"completion":480,"start":481,"enrollment":482,"conditions":1276,"interventions":1277},[63],[31],[429,485,398],{"nctId":487,"briefTitle":488,"status":81,"phases":1279,"primaryCompletion":490,"completion":491,"start":492,"enrollment":312,"conditions":1280,"interventions":1281},[63],[18],[495,398,485],{"nctId":1283,"briefTitle":1284,"status":81,"phases":1285,"primaryCompletion":1286,"completion":1286,"start":973,"enrollment":312,"conditions":1287,"interventions":1289},"NCT00193492","A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma",[63],"2013-03",[1288],"Lymphoma, Follicular",[485,102],{"nctId":1291,"briefTitle":1292,"status":81,"phases":1293,"primaryCompletion":445,"completion":1294,"start":560,"enrollment":871,"conditions":1295,"interventions":1297},"NCT00323739","Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma",[63],"2011-03",[1296],"Kidney Cancer",[474,1298],"RAD001",{"nctId":1300,"briefTitle":1301,"status":81,"phases":1302,"primaryCompletion":1303,"completion":479,"start":1304,"enrollment":1305,"conditions":1306,"interventions":1307},"NCT00915603","Trial of Paclitaxel\u002FBevacizumab +\u002F- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer",[63],"2014-06","2009-07",113,[23],[650,485,440,485,440],{"nctId":1309,"briefTitle":1310,"status":81,"phases":1311,"primaryCompletion":1312,"completion":161,"start":1313,"enrollment":1314,"conditions":1315,"interventions":1316},"NCT00193154","OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma",[63],"2004-01","2003-02",63,[1296],[1317,485],"OSI-774",{"nctId":1319,"briefTitle":1320,"status":81,"phases":1321,"primaryCompletion":1032,"completion":720,"start":1322,"enrollment":1323,"conditions":1324,"interventions":1325},"NCT01121939","Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers",[63],"2010-05",43,[503],[485,1326,1327],"Pertuzumab","Sandostatin LAR® Depot",{"nctId":1329,"briefTitle":1330,"status":81,"phases":1331,"primaryCompletion":1332,"completion":1333,"start":132,"enrollment":1334,"conditions":1335,"interventions":1336},"NCT00591734","RAD001 Plus Bevacizumab in Metastatic Melanoma",[63],"2010-10","2011-10",57,[648],[485,650],{"nctId":1338,"briefTitle":1339,"status":81,"phases":1340,"primaryCompletion":945,"completion":625,"start":742,"enrollment":1341,"conditions":1342,"interventions":1344},"NCT00193258","Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma",[62,63],94,[1343],"Clear Cell Renal Cell Carcinoma",[485,630,698],{"nctId":517,"briefTitle":518,"status":159,"phases":1346,"primaryCompletion":436,"completion":436,"start":520,"enrollment":8,"conditions":1347,"interventions":1348},[63],[18],[485,429,473],{"nctId":1350,"briefTitle":1351,"status":81,"phases":1352,"primaryCompletion":636,"completion":1353,"start":457,"enrollment":1354,"conditions":1355,"interventions":1357},"NCT00455975","High-dose Bevacizumab in Advanced Renal Carcinoma Patients",[63],"2013-09",119,[1356,1296],"Renal Cancer",[485],{"nctId":1040,"briefTitle":1041,"status":81,"phases":1359,"primaryCompletion":423,"completion":423,"start":1043,"enrollment":425,"conditions":1360,"interventions":1361},[63],[33],[1046,485,576,576,1026,852],{"nctId":1363,"briefTitle":1364,"status":81,"phases":1365,"primaryCompletion":490,"completion":1366,"start":666,"enrollment":1367,"conditions":1368,"interventions":1369},"NCT00392392","Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer",[63],"2011-12",29,[15],[990,485,515],{"nctId":548,"briefTitle":549,"status":159,"phases":1371,"primaryCompletion":551,"completion":552,"start":553,"enrollment":9,"conditions":1372,"interventions":1373},[63],[26],[398,440,485],{"nctId":578,"briefTitle":579,"status":81,"phases":1375,"primaryCompletion":581,"completion":582,"start":583,"enrollment":312,"conditions":1376,"interventions":1377},[63],[585],[587,473,474,588],{"nctId":1379,"briefTitle":1380,"status":81,"phases":1381,"primaryCompletion":424,"completion":527,"start":520,"enrollment":1382,"conditions":1383,"interventions":1385},"NCT00405938","Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer",[63],79,[15,1384],"Breast Neoplasms",[485,1386,1387],"Anastrozole","Fulvestrant",{"nctId":1389,"briefTitle":1390,"status":159,"phases":1391,"primaryCompletion":479,"completion":479,"start":162,"enrollment":19,"conditions":1392,"interventions":1394},"NCT00972335","Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma",[63],[1393],"Intracranial Meningioma",[650,485],{"nctId":621,"briefTitle":622,"status":81,"phases":1396,"primaryCompletion":624,"completion":625,"start":457,"enrollment":626,"conditions":1397,"interventions":1398},[63],[628],[630,485,440,398,631],{"nctId":1400,"briefTitle":1401,"status":81,"phases":1402,"primaryCompletion":1403,"completion":552,"start":436,"enrollment":1404,"conditions":1405,"interventions":1406},"NCT00805961","RT, Temozolomide, and Bevacizumab Followed by Bevacizumab\u002FEverolimus in First-line Treatment of GBM",[63],"2009-10",68,[1245],[1407,485,485,650],"Temozolomide",{"nctId":652,"briefTitle":653,"status":81,"phases":1409,"primaryCompletion":655,"completion":436,"start":656,"enrollment":657,"conditions":1410,"interventions":1411},[63],[470],[472,473,474],{"nctId":1413,"briefTitle":1414,"status":81,"phases":1415,"primaryCompletion":1416,"completion":1417,"start":1366,"enrollment":1418,"conditions":1419,"interventions":1420},"NCT01349660","Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed\u002FRefractory Glioblastoma Multiforme",[62,63],"2016-12","2018-12-29",88,[1245],[485,1421],"BKM120",{"nctId":1052,"briefTitle":1053,"status":81,"phases":1423,"primaryCompletion":605,"completion":645,"start":467,"enrollment":1055,"conditions":1424,"interventions":1425},[63],[315,1057,33],[576,485,852,1026],{"nctId":700,"briefTitle":701,"status":81,"phases":1427,"primaryCompletion":616,"completion":528,"start":703,"enrollment":704,"conditions":1428,"interventions":1429},[63],[18],[429,90,485,398],{"nctId":708,"briefTitle":709,"status":81,"phases":1431,"primaryCompletion":711,"completion":528,"start":712,"enrollment":713,"conditions":1432,"interventions":1433},[63],[26],[514,398,485],{"nctId":726,"briefTitle":727,"status":81,"phases":1435,"primaryCompletion":551,"completion":729,"start":730,"enrollment":731,"conditions":1436,"interventions":1437},[63],[733],[440,398,485,630],{"trials":1439,"activeCount":73},[],{"trials":1441,"activeCount":73},[],{"trials":1443,"activeCount":73},[],{"intervention":415,"totalTrials":1445,"cells":1446},11,{"EARLY_PHASE1":1447,"PHASE1":1449,"PHASE2":1479,"PHASE3":1522,"PHASE4":1524,"NA":1526},{"trials":1448,"activeCount":73},[],{"trials":1450,"activeCount":73},[1451,1461,1465,1475],{"nctId":1452,"briefTitle":1453,"status":81,"phases":1454,"primaryCompletion":491,"completion":436,"start":467,"enrollment":907,"conditions":1455,"interventions":1458},"NCT00315861","Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies",[62],[165,1456,1457,18],"Endometrial Cancer","Cervical Cancer",[1459,1460],"pemetrexed","topotecan",{"nctId":406,"briefTitle":407,"status":81,"phases":1462,"primaryCompletion":409,"completion":410,"start":411,"enrollment":19,"conditions":1463,"interventions":1464},[62],[413],[415,398],{"nctId":1466,"briefTitle":1467,"status":159,"phases":1468,"primaryCompletion":1469,"completion":1469,"start":1470,"enrollment":399,"conditions":1471,"interventions":1472},"NCT02649673","LCL161 Plus Topotecan for Patients With Relapsed\u002FRefractory Small Cell Lung Cancer and Select Gynecologic Malignancies",[62],"2021-07-30","2016-03-23",[531,165],[1473,415,1474],"LCL161","Pegylated GCSF",{"nctId":767,"briefTitle":768,"status":81,"phases":1476,"primaryCompletion":770,"completion":436,"start":677,"enrollment":771,"conditions":1477,"interventions":1478},[62],[413],[415,451],{"trials":1480,"activeCount":73},[1481,1485,1492,1500,1504,1508,1515],{"nctId":602,"briefTitle":603,"status":81,"phases":1482,"primaryCompletion":605,"completion":606,"start":467,"enrollment":607,"conditions":1483,"interventions":1484},[63],[609],[415,473],{"nctId":1486,"briefTitle":1487,"status":81,"phases":1488,"primaryCompletion":741,"completion":1304,"start":656,"enrollment":1489,"conditions":1490,"interventions":1491},"NCT00294190","Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer",[63],38,[531,609],[415],{"nctId":1493,"briefTitle":1494,"status":81,"phases":1495,"primaryCompletion":742,"completion":1496,"start":1497,"enrollment":595,"conditions":1498,"interventions":1499},"NCT00193401","Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer",[63],"2004-11","2002-08",[18],[415],{"nctId":672,"briefTitle":673,"status":81,"phases":1501,"primaryCompletion":675,"completion":676,"start":677,"enrollment":657,"conditions":1502,"interventions":1503},[63],[679],[415,440,398],{"nctId":868,"briefTitle":869,"status":81,"phases":1505,"primaryCompletion":793,"completion":436,"start":437,"enrollment":871,"conditions":1506,"interventions":1507},[63],[18],[415,451],{"nctId":1509,"briefTitle":1510,"status":81,"phases":1511,"primaryCompletion":1512,"completion":1512,"start":1312,"enrollment":595,"conditions":1513,"interventions":1514},"NCT00193167","Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer",[63],"2006-04",[314],[415],{"nctId":1516,"briefTitle":1517,"status":81,"phases":1518,"primaryCompletion":1519,"completion":457,"start":695,"enrollment":121,"conditions":1520,"interventions":1521},"NCT00193388","Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer",[63],"2004-12",[18],[415],{"trials":1523,"activeCount":73},[],{"trials":1525,"activeCount":73},[],{"trials":1527,"activeCount":73},[],{"intervention":630,"totalTrials":24,"cells":1529},{"EARLY_PHASE1":1530,"PHASE1":1532,"PHASE2":1542,"PHASE3":1582,"PHASE4":1584,"NA":1586},{"trials":1531,"activeCount":73},[],{"trials":1533,"activeCount":73},[1534],{"nctId":1535,"briefTitle":1536,"status":81,"phases":1537,"primaryCompletion":1353,"completion":1303,"start":561,"enrollment":1538,"conditions":1539,"interventions":1541},"NCT00759928","PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors",[62],48,[1540],"Refractory Solid Tumors",[630,670],{"trials":1543,"activeCount":73},[1544,1548,1552,1556,1560,1567,1571,1578],{"nctId":1253,"briefTitle":1254,"status":81,"phases":1545,"primaryCompletion":973,"completion":436,"start":447,"enrollment":657,"conditions":1546,"interventions":1547},[63],[753],[485,630],{"nctId":1263,"briefTitle":1264,"status":81,"phases":1549,"primaryCompletion":730,"completion":1266,"start":1267,"enrollment":312,"conditions":1550,"interventions":1551},[63],[686],[485,630,440,631],{"nctId":1338,"briefTitle":1339,"status":81,"phases":1553,"primaryCompletion":945,"completion":625,"start":742,"enrollment":1341,"conditions":1554,"interventions":1555},[62,63],[1343],[485,630,698],{"nctId":578,"briefTitle":579,"status":81,"phases":1557,"primaryCompletion":581,"completion":582,"start":583,"enrollment":312,"conditions":1558,"interventions":1559},[63],[585],[587,473,474,588],{"nctId":1561,"briefTitle":1562,"status":81,"phases":1563,"primaryCompletion":1266,"completion":1564,"start":780,"enrollment":111,"conditions":1565,"interventions":1566},"NCT00609804","Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib",[63],"2014-11",[26],[670,630],{"nctId":621,"briefTitle":622,"status":81,"phases":1568,"primaryCompletion":624,"completion":625,"start":457,"enrollment":626,"conditions":1569,"interventions":1570},[63],[628],[630,485,440,398,631],{"nctId":1572,"briefTitle":1573,"status":81,"phases":1574,"primaryCompletion":665,"completion":1303,"start":162,"enrollment":1575,"conditions":1576,"interventions":1577},"NCT01027598","Randomized, Double-Blind Trial of Erlotinib\u002FPazopanib or Erlotinib\u002FPlacebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer",[63],202,[31],[169,630],{"nctId":726,"briefTitle":727,"status":81,"phases":1579,"primaryCompletion":551,"completion":729,"start":730,"enrollment":731,"conditions":1580,"interventions":1581},[63],[733],[440,398,485,630],{"trials":1583,"activeCount":73},[],{"trials":1585,"activeCount":73},[],{"trials":1587,"activeCount":73},[],{"intervention":102,"totalTrials":24,"cells":1589},{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1606,"PHASE3":1661,"PHASE4":1663,"NA":1665},{"trials":1591,"activeCount":73},[],{"trials":1593,"activeCount":73},[1594],{"nctId":1595,"briefTitle":1596,"status":81,"phases":1597,"primaryCompletion":1598,"completion":1598,"start":552,"enrollment":1538,"conditions":1599,"interventions":1603},"NCT01871675","Study of IPI-145 in Combination With Rituximab or Bendamustine\u002FRituximab in Hematologic Malignancies",[62],"2016-06",[1600,135,1601,1602],"Lymphoma","Non-Hodgkin Lymphoma","T-cell Lymphoma",[1604,102,1605],"IPI-145","Bendamustine",{"trials":1607,"activeCount":73},[1608,1615,1619,1631,1639,1649,1653,1657],{"nctId":1609,"briefTitle":1610,"status":81,"phases":1611,"primaryCompletion":511,"completion":838,"start":1612,"enrollment":468,"conditions":1613,"interventions":1614},"NCT01029730","Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma",[63],"2010-03",[1600],[1605,103,102],{"nctId":1283,"briefTitle":1284,"status":81,"phases":1616,"primaryCompletion":1286,"completion":1286,"start":973,"enrollment":312,"conditions":1617,"interventions":1618},[63],[1288],[485,102],{"nctId":1620,"briefTitle":1621,"status":81,"phases":1622,"primaryCompletion":1623,"completion":616,"start":1624,"enrollment":1625,"conditions":1626,"interventions":1627},"NCT00193479","Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma",[63],"2008-07","2003-04",51,[597],[844,1628,1629,1630,102],"Mitoxantrone","Vincristine","Prednisone",{"nctId":1632,"briefTitle":1633,"status":81,"phases":1634,"primaryCompletion":500,"completion":490,"start":1635,"enrollment":595,"conditions":1636,"interventions":1637},"NCT00193466","Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[63],"2002-01",[597],[102,138,1638],"CAMPTH-1H",{"nctId":1640,"briefTitle":1641,"status":81,"phases":1642,"primaryCompletion":447,"completion":436,"start":1643,"enrollment":595,"conditions":1644,"interventions":1645},"NCT00193440","Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma",[63],"2002-04",[597],[102,1646,1647,1648],"CHOP","CVP","Ibritumomab Tiuxetan",{"nctId":590,"briefTitle":591,"status":81,"phases":1650,"primaryCompletion":593,"completion":593,"start":594,"enrollment":595,"conditions":1651,"interventions":1652},[63],[597],[599,398,505,102,600],{"nctId":92,"briefTitle":93,"status":81,"phases":1654,"primaryCompletion":95,"completion":96,"start":97,"enrollment":98,"conditions":1655,"interventions":1656},[62,63],[100],[102,103,69],{"nctId":128,"briefTitle":129,"status":81,"phases":1658,"primaryCompletion":131,"completion":96,"start":132,"enrollment":133,"conditions":1659,"interventions":1660},[62,63],[135],[137,102,138],{"trials":1662,"activeCount":73},[],{"trials":1664,"activeCount":73},[],{"trials":1666,"activeCount":73},[],{"intervention":852,"totalTrials":1668,"cells":1669},8,{"EARLY_PHASE1":1670,"PHASE1":1672,"PHASE2":1674,"PHASE3":1713,"PHASE4":1715,"NA":1717},{"trials":1671,"activeCount":73},[],{"trials":1673,"activeCount":73},[],{"trials":1675,"activeCount":73},[1676,1683,1687,1691,1697,1701,1705,1709],{"nctId":1677,"briefTitle":1678,"status":81,"phases":1679,"primaryCompletion":490,"completion":436,"start":1680,"enrollment":1538,"conditions":1681,"interventions":1682},"NCT00193609","Oxaliplatin and Capecitabine in the Treatment of Relapsed\u002FRefractory Carcinoma of Unknown Primary Site",[63],"2004-09",[753],[852,853],{"nctId":1019,"briefTitle":1020,"status":81,"phases":1684,"primaryCompletion":97,"completion":1022,"start":886,"enrollment":173,"conditions":1685,"interventions":1686},[63],[314],[485,890,1025,1026,852],{"nctId":1028,"briefTitle":1029,"status":159,"phases":1688,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":1689,"interventions":1690},[63],[1036],[576,852,1038],{"nctId":1692,"briefTitle":1693,"status":81,"phases":1694,"primaryCompletion":561,"completion":1332,"start":656,"enrollment":16,"conditions":1695,"interventions":1696},"NCT00297596","Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer",[63],[15],[515,852],{"nctId":1040,"briefTitle":1041,"status":81,"phases":1698,"primaryCompletion":423,"completion":423,"start":1043,"enrollment":425,"conditions":1699,"interventions":1700},[63],[33],[1046,485,576,576,1026,852],{"nctId":846,"briefTitle":847,"status":81,"phases":1702,"primaryCompletion":581,"completion":436,"start":447,"enrollment":849,"conditions":1703,"interventions":1704},[62,63],[574],[852,451,853],{"nctId":1052,"briefTitle":1053,"status":81,"phases":1706,"primaryCompletion":605,"completion":645,"start":467,"enrollment":1055,"conditions":1707,"interventions":1708},[63],[315,1057,33],[576,485,852,1026],{"nctId":1060,"briefTitle":1061,"status":81,"phases":1710,"primaryCompletion":161,"completion":161,"start":1063,"enrollment":907,"conditions":1711,"interventions":1712},[63],[33],[430,852,495,1026,576],{"trials":1714,"activeCount":73},[],{"trials":1716,"activeCount":73},[],{"trials":1718,"activeCount":73},[],{"intervention":429,"totalTrials":1668,"cells":1720},{"EARLY_PHASE1":1721,"PHASE1":1723,"PHASE2":1729,"PHASE3":1768,"PHASE4":1770,"NA":1772},{"trials":1722,"activeCount":73},[],{"trials":1724,"activeCount":73},[1725],{"nctId":1452,"briefTitle":1453,"status":81,"phases":1726,"primaryCompletion":491,"completion":436,"start":467,"enrollment":907,"conditions":1727,"interventions":1728},[62],[165,1456,1457,18],[1459,1460],{"trials":1730,"activeCount":73},[1731,1735,1739,1743,1747,1751,1764],{"nctId":419,"briefTitle":420,"status":81,"phases":1732,"primaryCompletion":422,"completion":423,"start":424,"enrollment":425,"conditions":1733,"interventions":1734},[63],[427],[398,429,430],{"nctId":476,"briefTitle":477,"status":81,"phases":1736,"primaryCompletion":479,"completion":480,"start":481,"enrollment":482,"conditions":1737,"interventions":1738},[63],[31],[429,485,398],{"nctId":924,"briefTitle":925,"status":81,"phases":1740,"primaryCompletion":446,"completion":553,"start":410,"enrollment":86,"conditions":1741,"interventions":1742},[63],[18],[429,90],{"nctId":517,"briefTitle":518,"status":159,"phases":1744,"primaryCompletion":436,"completion":436,"start":520,"enrollment":8,"conditions":1745,"interventions":1746},[63],[18],[485,429,473],{"nctId":700,"briefTitle":701,"status":81,"phases":1748,"primaryCompletion":616,"completion":528,"start":703,"enrollment":704,"conditions":1749,"interventions":1750},[63],[18],[429,90,485,398],{"nctId":1752,"briefTitle":1753,"status":1754,"phases":1755,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":73,"conditions":1759,"interventions":1761},"NCT05948462","Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib","WITHDRAWN",[63],"2025-03","2025-09","2023-11",[18,1760],"Non-small Cell Lung Cancer",[1762,1763,429],"Lorlatinib","Cisplatin or Carboplatin",{"nctId":717,"briefTitle":718,"status":81,"phases":1765,"primaryCompletion":720,"completion":721,"start":481,"enrollment":722,"conditions":1766,"interventions":1767},[63],[31],[429,398],{"trials":1769,"activeCount":73},[],{"trials":1771,"activeCount":73},[],{"trials":1773,"activeCount":73},[],{"intervention":650,"totalTrials":1668,"cells":1775},{"EARLY_PHASE1":1776,"PHASE1":1778,"PHASE2":1796,"PHASE3":1830,"PHASE4":1832,"NA":1834},{"trials":1777,"activeCount":73},[],{"trials":1779,"activeCount":73},[1780,1788],{"nctId":1781,"briefTitle":1782,"status":81,"phases":1783,"primaryCompletion":1784,"completion":1784,"start":511,"enrollment":1489,"conditions":1785,"interventions":1786},"NCT02125084","Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer",[62],"2021-05-03",[29],[650,1787],"Enzalutamide",{"nctId":1789,"briefTitle":1790,"status":81,"phases":1791,"primaryCompletion":552,"completion":552,"start":1022,"enrollment":19,"conditions":1792,"interventions":1794},"NCT01154335","Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer",[62],[1793],"Metastatic Colorectal Cancer",[1795,650],"OSI-906",{"trials":1797,"activeCount":73},[1798,1802,1814,1818,1822,1826],{"nctId":1300,"briefTitle":1301,"status":81,"phases":1799,"primaryCompletion":1303,"completion":479,"start":1304,"enrollment":1305,"conditions":1800,"interventions":1801},[63],[23],[650,485,440,485,440],{"nctId":1803,"briefTitle":1804,"status":81,"phases":1805,"primaryCompletion":1806,"completion":1806,"start":1807,"enrollment":1538,"conditions":1808,"interventions":1809},"NCT02291913","Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer",[63],"2019-01-31","2014-12-18",[15],[650,1810,1811,1387,1386,1812,1813],"Exemestane","Tamoxifen","Letrozole","Toremifine",{"nctId":1329,"briefTitle":1330,"status":81,"phases":1815,"primaryCompletion":1332,"completion":1333,"start":132,"enrollment":1334,"conditions":1816,"interventions":1817},[63],[648],[485,650],{"nctId":1389,"briefTitle":1390,"status":159,"phases":1819,"primaryCompletion":479,"completion":479,"start":162,"enrollment":19,"conditions":1820,"interventions":1821},[63],[1393],[650,485],{"nctId":1400,"briefTitle":1401,"status":81,"phases":1823,"primaryCompletion":1403,"completion":552,"start":436,"enrollment":1404,"conditions":1824,"interventions":1825},[63],[1245],[1407,485,485,650],{"nctId":642,"briefTitle":643,"status":81,"phases":1827,"primaryCompletion":645,"completion":646,"start":616,"enrollment":425,"conditions":1828,"interventions":1829},[63],[648],[440,398,650],{"trials":1831,"activeCount":73},[],{"trials":1833,"activeCount":73},[],{"trials":1835,"activeCount":73},[],{"intervention":103,"totalTrials":1010,"cells":1837},{"EARLY_PHASE1":1838,"PHASE1":1840,"PHASE2":1842,"PHASE3":1885,"PHASE4":1887,"NA":1889},{"trials":1839,"activeCount":73},[],{"trials":1841,"activeCount":73},[],{"trials":1843,"activeCount":73},[1844,1848,1852,1861,1865,1872,1878],{"nctId":1609,"briefTitle":1610,"status":81,"phases":1845,"primaryCompletion":511,"completion":838,"start":1612,"enrollment":468,"conditions":1846,"interventions":1847},[63],[1600],[1605,103,102],{"nctId":790,"briefTitle":791,"status":81,"phases":1849,"primaryCompletion":793,"completion":457,"start":409,"enrollment":657,"conditions":1850,"interventions":1851},[63],[29],[451,103],{"nctId":1853,"briefTitle":1854,"status":159,"phases":1855,"primaryCompletion":1856,"completion":1856,"start":1857,"enrollment":1010,"conditions":1858,"interventions":1859},"NCT02254551","Safety\u002FEfficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed\u002FRefractory Multiple Myeloma",[63],"2015-10","2015-01",[21],[1860,103],"LDE225",{"nctId":92,"briefTitle":93,"status":81,"phases":1862,"primaryCompletion":95,"completion":96,"start":97,"enrollment":98,"conditions":1863,"interventions":1864},[62,63],[100],[102,103,69],{"nctId":1866,"briefTitle":1867,"status":81,"phases":1868,"primaryCompletion":720,"completion":1869,"start":1322,"enrollment":849,"conditions":1870,"interventions":1871},"NCT01056276","Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy",[63],"2017-02",[21],[1605,103,115],{"nctId":1873,"briefTitle":1874,"status":81,"phases":1875,"primaryCompletion":560,"completion":436,"start":409,"enrollment":595,"conditions":1876,"interventions":1877},"NCT00193557","Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma",[63],[21],[103],{"nctId":1879,"briefTitle":1880,"status":81,"phases":1881,"primaryCompletion":616,"completion":1882,"start":946,"enrollment":11,"conditions":1883,"interventions":1884},"NCT00536575","Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients",[62,63],"2010-08",[21],[103,670],{"trials":1886,"activeCount":73},[],{"trials":1888,"activeCount":73},[],{"trials":1890,"activeCount":73},[],{"intervention":853,"totalTrials":8,"cells":1892},{"EARLY_PHASE1":1893,"PHASE1":1895,"PHASE2":1913,"PHASE3":1931,"PHASE4":1933,"NA":1935},{"trials":1894,"activeCount":73},[],{"trials":1896,"activeCount":73},[1897,1904],{"nctId":1898,"briefTitle":1899,"status":81,"phases":1900,"primaryCompletion":436,"completion":510,"start":491,"enrollment":771,"conditions":1901,"interventions":1902},"NCT00632489","LBH589 in Combination With Capecitabine Plus\u002FMinus (±) Lapatinib in Breast Cancer Patients",[62],[15],[1903,853,1038],"LBH589",{"nctId":1905,"briefTitle":1906,"status":81,"phases":1907,"primaryCompletion":636,"completion":1303,"start":1908,"enrollment":947,"conditions":1909,"interventions":1911},"NCT01226732","A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors",[62],"2010-11",[1910],"Metastatic or Unresectable Solid Tumor Malignancy",[853,1912],"Hsp90 Inhibitor AUY 922",{"trials":1914,"activeCount":73},[1915,1919,1927],{"nctId":1677,"briefTitle":1678,"status":81,"phases":1916,"primaryCompletion":490,"completion":436,"start":1680,"enrollment":1538,"conditions":1917,"interventions":1918},[63],[753],[852,853],{"nctId":1920,"briefTitle":1921,"status":159,"phases":1922,"primaryCompletion":1923,"completion":424,"start":817,"enrollment":595,"conditions":1924,"interventions":1925},"NCT00193102","Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer",[63],"2005-02",[15],[1926,853],"Thalidomide",{"nctId":846,"briefTitle":847,"status":81,"phases":1928,"primaryCompletion":581,"completion":436,"start":447,"enrollment":849,"conditions":1929,"interventions":1930},[62,63],[574],[852,451,853],{"trials":1932,"activeCount":73},[],{"trials":1934,"activeCount":73},[],{"trials":1936,"activeCount":73},[],{"intervention":1026,"totalTrials":9,"cells":1938},{"EARLY_PHASE1":1939,"PHASE1":1941,"PHASE2":1943,"PHASE3":1961,"PHASE4":1963,"NA":1965},{"trials":1940,"activeCount":73},[],{"trials":1942,"activeCount":73},[],{"trials":1944,"activeCount":73},[1945,1949,1953,1957],{"nctId":1019,"briefTitle":1020,"status":81,"phases":1946,"primaryCompletion":97,"completion":1022,"start":886,"enrollment":173,"conditions":1947,"interventions":1948},[63],[314],[485,890,1025,1026,852],{"nctId":1040,"briefTitle":1041,"status":81,"phases":1950,"primaryCompletion":423,"completion":423,"start":1043,"enrollment":425,"conditions":1951,"interventions":1952},[63],[33],[1046,485,576,576,1026,852],{"nctId":1052,"briefTitle":1053,"status":81,"phases":1954,"primaryCompletion":605,"completion":645,"start":467,"enrollment":1055,"conditions":1955,"interventions":1956},[63],[315,1057,33],[576,485,852,1026],{"nctId":1060,"briefTitle":1061,"status":81,"phases":1958,"primaryCompletion":161,"completion":161,"start":1063,"enrollment":907,"conditions":1959,"interventions":1960},[63],[33],[430,852,495,1026,576],{"trials":1962,"activeCount":73},[],{"trials":1964,"activeCount":73},[],{"trials":1966,"activeCount":73},[],{"intervention":1605,"totalTrials":9,"cells":1968},{"EARLY_PHASE1":1969,"PHASE1":1971,"PHASE2":1977,"PHASE3":1998,"PHASE4":2000,"NA":2002},{"trials":1970,"activeCount":73},[],{"trials":1972,"activeCount":73},[1973],{"nctId":1595,"briefTitle":1596,"status":81,"phases":1974,"primaryCompletion":1598,"completion":1598,"start":552,"enrollment":1538,"conditions":1975,"interventions":1976},[62],[1600,135,1601,1602],[1604,102,1605],{"trials":1978,"activeCount":73},[1979,1983,1994],{"nctId":1609,"briefTitle":1610,"status":81,"phases":1980,"primaryCompletion":511,"completion":838,"start":1612,"enrollment":468,"conditions":1981,"interventions":1982},[63],[1600],[1605,103,102],{"nctId":1984,"briefTitle":1985,"status":81,"phases":1986,"primaryCompletion":1987,"completion":1988,"start":1989,"enrollment":163,"conditions":1990,"interventions":1992},"NCT01626352","Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy",[63],"2016-09","2017-04","2012-10",[1991],"Diffuse Large B-Cell Lymphoma",[1605,1993],"Ofatumumab",{"nctId":1866,"briefTitle":1867,"status":81,"phases":1995,"primaryCompletion":720,"completion":1869,"start":1322,"enrollment":849,"conditions":1996,"interventions":1997},[63],[21],[1605,103,115],{"trials":1999,"activeCount":73},[],{"trials":2001,"activeCount":73},[],{"trials":2003,"activeCount":73},[],{"intervention":990,"totalTrials":9,"cells":2005},{"EARLY_PHASE1":2006,"PHASE1":2008,"PHASE2":2019,"PHASE3":2039,"PHASE4":2041,"NA":2043},{"trials":2007,"activeCount":73},[],{"trials":2009,"activeCount":73},[2010],{"nctId":2011,"briefTitle":2012,"status":1754,"phases":2013,"primaryCompletion":2014,"completion":2014,"start":1156,"enrollment":73,"conditions":2015,"interventions":2017},"NCT02300935","Study of Trametinib and Nab-paclitaxel in Patients With Melanoma",[62],"2016-01-20",[2016],"Melanoma",[2018,990],"trametinib",{"trials":2020,"activeCount":73},[2021,2025,2035],{"nctId":1363,"briefTitle":1364,"status":81,"phases":2022,"primaryCompletion":490,"completion":1366,"start":666,"enrollment":1367,"conditions":2023,"interventions":2024},[63],[15],[990,485,515],{"nctId":2026,"briefTitle":2027,"status":81,"phases":2028,"primaryCompletion":2029,"completion":2029,"start":2030,"enrollment":1243,"conditions":2031,"interventions":2033},"NCT02317991","Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer",[63],"2021-05-21","2015-05-05",[2032],"Gastroesophageal Cancer",[990,2034],"ramucirumab",{"nctId":979,"briefTitle":980,"status":159,"phases":2036,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":2037,"interventions":2038},[63],[986,987,988],[990,90],{"trials":2040,"activeCount":73},[],{"trials":2042,"activeCount":73},[],{"trials":2044,"activeCount":73},[],{"intervention":430,"totalTrials":984,"cells":2046},{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2051,"PHASE3":2065,"PHASE4":2067,"NA":2069},{"trials":2048,"activeCount":73},[],{"trials":2050,"activeCount":73},[],{"trials":2052,"activeCount":73},[2053,2057,2061],{"nctId":419,"briefTitle":420,"status":81,"phases":2054,"primaryCompletion":422,"completion":423,"start":424,"enrollment":425,"conditions":2055,"interventions":2056},[63],[427],[398,429,430],{"nctId":612,"briefTitle":613,"status":81,"phases":2058,"primaryCompletion":615,"completion":615,"start":616,"enrollment":617,"conditions":2059,"interventions":2060},[63],[23],[430,398,90],{"nctId":1060,"briefTitle":1061,"status":81,"phases":2062,"primaryCompletion":161,"completion":161,"start":1063,"enrollment":907,"conditions":2063,"interventions":2064},[63],[33],[430,852,495,1026,576],{"trials":2066,"activeCount":73},[],{"trials":2068,"activeCount":73},[],{"trials":2070,"activeCount":73},[],{"intervention":784,"totalTrials":984,"cells":2072},{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2091,"PHASE4":2093,"NA":2095},{"trials":2074,"activeCount":73},[],{"trials":2076,"activeCount":73},[],{"trials":2078,"activeCount":73},[2079,2083,2087],{"nctId":777,"briefTitle":778,"status":81,"phases":2080,"primaryCompletion":780,"completion":582,"start":781,"enrollment":704,"conditions":2081,"interventions":2082},[63],[15],[90,784,451],{"nctId":827,"briefTitle":828,"status":159,"phases":2084,"primaryCompletion":594,"completion":569,"start":830,"enrollment":831,"conditions":2085,"interventions":2086},[63],[15],[451,784],{"nctId":970,"briefTitle":971,"status":81,"phases":2088,"primaryCompletion":561,"completion":956,"start":973,"enrollment":974,"conditions":2089,"interventions":2090},[63],[15],[90,784,977],{"trials":2092,"activeCount":73},[],{"trials":2094,"activeCount":73},[],{"trials":2096,"activeCount":73},[],{"intervention":1038,"totalTrials":984,"cells":2098},{"EARLY_PHASE1":2099,"PHASE1":2101,"PHASE2":2107,"PHASE3":2124,"PHASE4":2126,"NA":2128},{"trials":2100,"activeCount":73},[],{"trials":2102,"activeCount":73},[2103],{"nctId":1898,"briefTitle":1899,"status":81,"phases":2104,"primaryCompletion":436,"completion":510,"start":491,"enrollment":771,"conditions":2105,"interventions":2106},[62],[15],[1903,853,1038],{"trials":2108,"activeCount":73},[2109,2113],{"nctId":1028,"briefTitle":1029,"status":159,"phases":2110,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":2111,"interventions":2112},[63],[1036],[576,852,1038],{"nctId":2114,"briefTitle":2115,"status":159,"phases":2116,"primaryCompletion":2117,"completion":1988,"start":2118,"enrollment":1445,"conditions":2119,"interventions":2121},"NCT01934894","Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases",[63],"2016-02","2014-05",[2120],"Metastatic Breast Cancer With Intracranial Metastases",[2122,2123],"cabazitaxel","lapatinib",{"trials":2125,"activeCount":73},[],{"trials":2127,"activeCount":73},[],{"trials":2129,"activeCount":73},[],{"intervention":698,"totalTrials":984,"cells":2131},{"EARLY_PHASE1":2132,"PHASE1":2134,"PHASE2":2136,"PHASE3":2150,"PHASE4":2152,"NA":2154},{"trials":2133,"activeCount":73},[],{"trials":2135,"activeCount":73},[],{"trials":2137,"activeCount":73},[2138,2142,2146],{"nctId":1338,"briefTitle":1339,"status":81,"phases":2139,"primaryCompletion":945,"completion":625,"start":742,"enrollment":1341,"conditions":2140,"interventions":2141},[62,63],[1343],[485,630,698],{"nctId":821,"briefTitle":822,"status":81,"phases":2143,"primaryCompletion":491,"completion":436,"start":410,"enrollment":529,"conditions":2144,"interventions":2145},[63],[15],[698,451],{"nctId":691,"briefTitle":692,"status":81,"phases":2147,"primaryCompletion":694,"completion":694,"start":695,"enrollment":312,"conditions":2148,"interventions":2149},[63],[18],[698,495,398],{"trials":2151,"activeCount":73},[],{"trials":2153,"activeCount":73},[],{"trials":2155,"activeCount":73},[],{"intervention":1993,"totalTrials":984,"cells":2157},{"EARLY_PHASE1":2158,"PHASE1":2160,"PHASE2":2162,"PHASE3":2184,"PHASE4":2186,"NA":2188},{"trials":2159,"activeCount":73},[],{"trials":2161,"activeCount":73},[],{"trials":2163,"activeCount":73},[2164,2168,2175],{"nctId":1984,"briefTitle":1985,"status":81,"phases":2165,"primaryCompletion":1987,"completion":1988,"start":1989,"enrollment":163,"conditions":2166,"interventions":2167},[63],[1991],[1605,1993],{"nctId":2169,"briefTitle":2170,"status":81,"phases":2171,"primaryCompletion":1156,"completion":2172,"start":636,"enrollment":399,"conditions":2173,"interventions":2174},"NCT01848145","Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia",[63],"2017-03",[135],[1993],{"nctId":2176,"briefTitle":2177,"status":81,"phases":2178,"primaryCompletion":539,"completion":2179,"start":1022,"enrollment":2180,"conditions":2181,"interventions":2183},"NCT01113632","Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[63],"2016-08",77,[135,2182],"Small Lymphocytic Lymphoma",[1993],{"trials":2185,"activeCount":73},[],{"trials":2187,"activeCount":73},[],{"trials":2189,"activeCount":73},[],{"intervention":1903,"totalTrials":984,"cells":2191},{"EARLY_PHASE1":2192,"PHASE1":2194,"PHASE2":2200,"PHASE3":2216,"PHASE4":2218,"NA":2220},{"trials":2193,"activeCount":73},[],{"trials":2195,"activeCount":73},[2196],{"nctId":1898,"briefTitle":1899,"status":81,"phases":2197,"primaryCompletion":436,"completion":510,"start":491,"enrollment":771,"conditions":2198,"interventions":2199},[62],[15],[1903,853,1038],{"trials":2201,"activeCount":73},[2202,2210],{"nctId":2203,"briefTitle":2204,"status":1754,"phases":2205,"enrollment":73,"conditions":2206,"interventions":2208},"NCT01028313","A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease",[63],[2207],"Chronic Graft-Versus-Host Disease",[1903,2209],"Methylprednisolone",{"nctId":2211,"briefTitle":2212,"status":81,"phases":2213,"primaryCompletion":1612,"completion":424,"start":132,"enrollment":771,"conditions":2214,"interventions":2215},"NCT00550277","LBH589 Treatment for Refractory Clear Cell Renal Carcinoma",[63],[1247],[1903],{"trials":2217,"activeCount":73},[],{"trials":2219,"activeCount":73},[],{"trials":2221,"activeCount":73},[],{"intervention":169,"totalTrials":984,"cells":2223},{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2228,"PHASE3":2245,"PHASE4":2247,"NA":2249},{"trials":2225,"activeCount":73},[],{"trials":2227,"activeCount":73},[],{"trials":2229,"activeCount":73},[2230,2234,2238],{"nctId":1572,"briefTitle":1573,"status":81,"phases":2231,"primaryCompletion":665,"completion":1303,"start":162,"enrollment":1575,"conditions":2232,"interventions":2233},[63],[31],[169,630],{"nctId":157,"briefTitle":158,"status":159,"phases":2235,"primaryCompletion":84,"completion":161,"start":162,"enrollment":163,"conditions":2236,"interventions":2237},[62,63],[165,166,167],[169,147],{"nctId":2239,"briefTitle":2240,"status":81,"phases":2241,"primaryCompletion":2242,"completion":528,"start":712,"enrollment":1334,"conditions":2243,"interventions":2244},"NCT00731211","Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma",[63],"2011-05",[1247],[169],{"trials":2246,"activeCount":73},[],{"trials":2248,"activeCount":73},[],{"trials":2250,"activeCount":73},[],{"intervention":2252,"totalTrials":984,"cells":2253},"Vinflunine",{"EARLY_PHASE1":2254,"PHASE1":2256,"PHASE2":2258,"PHASE3":2279,"PHASE4":2281,"NA":2283},{"trials":2255,"activeCount":73},[],{"trials":2257,"activeCount":73},[],{"trials":2259,"activeCount":73},[2260,2267,2273],{"nctId":2261,"briefTitle":2262,"status":81,"phases":2263,"primaryCompletion":956,"completion":606,"start":2264,"enrollment":1625,"conditions":2265,"interventions":2266},"NCT00284154","Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer",[63],"2006-01",[609,18],[2252],{"nctId":2268,"briefTitle":2269,"status":81,"phases":2270,"primaryCompletion":132,"completion":436,"start":655,"enrollment":958,"conditions":2271,"interventions":2272},"NCT00545766","Vinflunine in Hormone Refractory Prostate Cancer (HRPC)",[63],[29],[2252],{"nctId":2274,"briefTitle":2275,"status":81,"phases":2276,"primaryCompletion":581,"completion":1908,"start":2264,"enrollment":859,"conditions":2277,"interventions":2278},"NCT00284180","Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer",[63],[1384,15],[2252,515],{"trials":2280,"activeCount":73},[],{"trials":2282,"activeCount":73},[],{"trials":2284,"activeCount":73},[],{"intervention":843,"totalTrials":148,"cells":2286},{"EARLY_PHASE1":2287,"PHASE1":2289,"PHASE2":2291,"PHASE3":2306,"PHASE4":2308,"NA":2310},{"trials":2288,"activeCount":73},[],{"trials":2290,"activeCount":73},[],{"trials":2292,"activeCount":73},[2293,2302],{"nctId":2294,"briefTitle":2295,"status":81,"phases":2296,"primaryCompletion":2297,"completion":2297,"start":2298,"enrollment":2299,"conditions":2300,"interventions":2301},"NCT01401959","Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy",[63],"2017-04-03","2011-09-23",127,[23],[843,515],{"nctId":835,"briefTitle":836,"status":81,"phases":2303,"primaryCompletion":615,"completion":838,"start":84,"enrollment":839,"conditions":2304,"interventions":2305},[63],[841],[843,844,451],{"trials":2307,"activeCount":73},[],{"trials":2309,"activeCount":73},[],{"trials":2311,"activeCount":73},[],{"intervention":2313,"totalTrials":148,"cells":2314},"Regorafenib",{"EARLY_PHASE1":2315,"PHASE1":2317,"PHASE2":2319,"PHASE3":2343,"PHASE4":2345,"NA":2347},{"trials":2316,"activeCount":73},[],{"trials":2318,"activeCount":73},[],{"trials":2320,"activeCount":73},[2321,2334],{"nctId":2322,"briefTitle":2323,"status":81,"phases":2324,"primaryCompletion":2325,"completion":2325,"start":2326,"enrollment":121,"conditions":2327,"interventions":2331},"NCT02795156","Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations",[63],"2022-08-17","2016-09-28",[2328,986,2329,2330],"Non-small Cell Lung Carcinoma","Gastrointestinal Carcinoma, Non-colon","Upper Aerodigestive Tract Carcinoma",[2332,2313,2333],"Afatinib","Cabozantinib",{"nctId":2335,"briefTitle":2336,"status":81,"phases":2337,"primaryCompletion":2338,"completion":2338,"start":479,"enrollment":2339,"conditions":2340,"interventions":2342},"NCT02195011","Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases",[63],"2017-06-04",26,[2341],"Colorectal Neoplasms",[2313],{"trials":2344,"activeCount":73},[],{"trials":2346,"activeCount":73},[],{"trials":2348,"activeCount":73},[],{"intervention":890,"totalTrials":148,"cells":2350},{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2355,"PHASE3":2365,"PHASE4":2367,"NA":2369},{"trials":2352,"activeCount":73},[],{"trials":2354,"activeCount":73},[],{"trials":2356,"activeCount":73},[2357,2361],{"nctId":1019,"briefTitle":1020,"status":81,"phases":2358,"primaryCompletion":97,"completion":1022,"start":886,"enrollment":173,"conditions":2359,"interventions":2360},[63],[314],[485,890,1025,1026,852],{"nctId":883,"briefTitle":884,"status":81,"phases":2362,"primaryCompletion":85,"completion":540,"start":886,"enrollment":887,"conditions":2363,"interventions":2364},[63],[18],[90,451,890],{"trials":2366,"activeCount":73},[],{"trials":2368,"activeCount":73},[],{"trials":2370,"activeCount":73},[],{"intervention":631,"totalTrials":148,"cells":2372},{"EARLY_PHASE1":2373,"PHASE1":2375,"PHASE2":2377,"PHASE3":2387,"PHASE4":2389,"NA":2391},{"trials":2374,"activeCount":73},[],{"trials":2376,"activeCount":73},[],{"trials":2378,"activeCount":73},[2379,2383],{"nctId":1263,"briefTitle":1264,"status":81,"phases":2380,"primaryCompletion":730,"completion":1266,"start":1267,"enrollment":312,"conditions":2381,"interventions":2382},[63],[686],[485,630,440,631],{"nctId":621,"briefTitle":622,"status":81,"phases":2384,"primaryCompletion":624,"completion":625,"start":457,"enrollment":626,"conditions":2385,"interventions":2386},[63],[628],[630,485,440,398,631],{"trials":2388,"activeCount":73},[],{"trials":2390,"activeCount":73},[],{"trials":2392,"activeCount":73},[],{"intervention":461,"totalTrials":148,"cells":2394},{"EARLY_PHASE1":2395,"PHASE1":2397,"PHASE2":2399,"PHASE3":2409,"PHASE4":2411,"NA":2413},{"trials":2396,"activeCount":73},[],{"trials":2398,"activeCount":73},[],{"trials":2400,"activeCount":73},[2401,2405],{"nctId":453,"briefTitle":454,"status":81,"phases":2402,"primaryCompletion":456,"completion":457,"start":458,"enrollment":121,"conditions":2403,"interventions":2404},[63],[29],[440,461,398],{"nctId":797,"briefTitle":798,"status":81,"phases":2406,"primaryCompletion":655,"completion":655,"start":770,"enrollment":800,"conditions":2407,"interventions":2408},[63],[29],[451,461],{"trials":2410,"activeCount":73},[],{"trials":2412,"activeCount":73},[],{"trials":2414,"activeCount":73},[],{"intervention":1298,"totalTrials":148,"cells":2416},{"EARLY_PHASE1":2417,"PHASE1":2419,"PHASE2":2421,"PHASE3":2435,"PHASE4":2437,"NA":2439},{"trials":2418,"activeCount":73},[],{"trials":2420,"activeCount":73},[],{"trials":2422,"activeCount":73},[2423,2427],{"nctId":1291,"briefTitle":1292,"status":81,"phases":2424,"primaryCompletion":445,"completion":1294,"start":560,"enrollment":871,"conditions":2425,"interventions":2426},[63],[1296],[474,1298],{"nctId":2428,"briefTitle":2429,"status":81,"phases":2430,"primaryCompletion":2431,"completion":2431,"start":1267,"enrollment":2432,"conditions":2433,"interventions":2434},"NCT00392821","Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer",[62,63],"2013-10",78,[1296],[670,1298],{"trials":2436,"activeCount":73},[],{"trials":2438,"activeCount":73},[],{"trials":2440,"activeCount":73},[],{"intervention":2442,"totalTrials":148,"cells":2443},"Panobinostat",{"EARLY_PHASE1":2444,"PHASE1":2446,"PHASE2":2448,"PHASE3":2466,"PHASE4":2468,"NA":2470},{"trials":2445,"activeCount":73},[],{"trials":2447,"activeCount":73},[],{"trials":2449,"activeCount":73},[2450,2457],{"nctId":2451,"briefTitle":2452,"status":159,"phases":2453,"primaryCompletion":1294,"completion":1294,"start":132,"enrollment":2339,"conditions":2454,"interventions":2456},"NCT00594230","LBH589 in Refractory Myelodysplastic Syndromes (MDS)",[63],[2455],"Myelodysplastic Syndromes (MDS)",[2442],{"nctId":2458,"briefTitle":2459,"status":81,"phases":2460,"primaryCompletion":2461,"completion":2461,"start":1366,"enrollment":871,"conditions":2462,"interventions":2463},"NCT01496118","Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed\u002FRefractory Multiple Myeloma",[62,63],"2020-12",[21],[2464,2465],"panobinostat","carfilzomib",{"trials":2467,"activeCount":73},[],{"trials":2469,"activeCount":73},[],{"trials":2471,"activeCount":73},[],{"intervention":1387,"totalTrials":148,"cells":2473},{"EARLY_PHASE1":2474,"PHASE1":2476,"PHASE2":2478,"PHASE3":2488,"PHASE4":2490,"NA":2492},{"trials":2475,"activeCount":73},[],{"trials":2477,"activeCount":73},[],{"trials":2479,"activeCount":73},[2480,2484],{"nctId":1803,"briefTitle":1804,"status":81,"phases":2481,"primaryCompletion":1806,"completion":1806,"start":1807,"enrollment":1538,"conditions":2482,"interventions":2483},[63],[15],[650,1810,1811,1387,1386,1812,1813],{"nctId":1379,"briefTitle":1380,"status":81,"phases":2485,"primaryCompletion":424,"completion":527,"start":520,"enrollment":1382,"conditions":2486,"interventions":2487},[63],[15,1384],[485,1386,1387],{"trials":2489,"activeCount":73},[],{"trials":2491,"activeCount":73},[],{"trials":2493,"activeCount":73},[],{"intervention":1386,"totalTrials":148,"cells":2495},{"EARLY_PHASE1":2496,"PHASE1":2498,"PHASE2":2500,"PHASE3":2510,"PHASE4":2512,"NA":2514},{"trials":2497,"activeCount":73},[],{"trials":2499,"activeCount":73},[],{"trials":2501,"activeCount":73},[2502,2506],{"nctId":1803,"briefTitle":1804,"status":81,"phases":2503,"primaryCompletion":1806,"completion":1806,"start":1807,"enrollment":1538,"conditions":2504,"interventions":2505},[63],[15],[650,1810,1811,1387,1386,1812,1813],{"nctId":1379,"briefTitle":1380,"status":81,"phases":2507,"primaryCompletion":424,"completion":527,"start":520,"enrollment":1382,"conditions":2508,"interventions":2509},[63],[15,1384],[485,1386,1387],{"trials":2511,"activeCount":73},[],{"trials":2513,"activeCount":73},[],{"trials":2515,"activeCount":73},[],{"intervention":1407,"totalTrials":148,"cells":2517},{"EARLY_PHASE1":2518,"PHASE1":2520,"PHASE2":2522,"PHASE3":2535,"PHASE4":2537,"NA":2539},{"trials":2519,"activeCount":73},[],{"trials":2521,"activeCount":73},[],{"trials":2523,"activeCount":73},[2524,2531],{"nctId":2525,"briefTitle":2526,"status":81,"phases":2527,"primaryCompletion":97,"completion":1882,"start":466,"enrollment":2528,"conditions":2529,"interventions":2530},"NCT00544817","Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme",[63],47,[1245],[1407,670],{"nctId":1400,"briefTitle":1401,"status":81,"phases":2532,"primaryCompletion":1403,"completion":552,"start":436,"enrollment":1404,"conditions":2533,"interventions":2534},[63],[1245],[1407,485,485,650],{"trials":2536,"activeCount":73},[],{"trials":2538,"activeCount":73},[],{"trials":2540,"activeCount":73},[],{"intervention":2542,"totalTrials":148,"cells":2543},"Nivolumab",{"EARLY_PHASE1":2544,"PHASE1":2546,"PHASE2":2559,"PHASE3":2571,"PHASE4":2573,"NA":2575},{"trials":2545,"activeCount":73},[],{"trials":2547,"activeCount":73},[2548],{"nctId":2549,"briefTitle":2550,"status":1754,"phases":2551,"primaryCompletion":2552,"completion":2552,"start":2553,"enrollment":73,"conditions":2554,"interventions":2558},"NCT04361058","Nivolumab for High-Risk MDS\u002FAML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide",[62],"2021-04-20","2020-04-13",[2555,2556,2557],"Leukemia, Myeloid, Acute","Myelodysplastic Syndromes","Myelodysplastic Syndrome Acute Myeloid Leukemia",[2542],{"trials":2560,"activeCount":73},[2561],{"nctId":2562,"briefTitle":2563,"status":81,"phases":2564,"primaryCompletion":2565,"completion":2566,"start":2567,"enrollment":529,"conditions":2568,"interventions":2570},"NCT03436862","Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse\u002FProgression Risk",[63],"2022-05-05","2023-04-04","2018-05-23",[2569],"Hodgkin Lymphoma",[2542],{"trials":2572,"activeCount":73},[],{"trials":2574,"activeCount":73},[],{"trials":2576,"activeCount":73},[],{"intervention":533,"totalTrials":148,"cells":2578},{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2583,"PHASE3":2593,"PHASE4":2595,"NA":2597},{"trials":2580,"activeCount":73},[],{"trials":2582,"activeCount":73},[],{"trials":2584,"activeCount":73},[2585,2589],{"nctId":524,"briefTitle":525,"status":81,"phases":2586,"primaryCompletion":527,"completion":528,"start":97,"enrollment":529,"conditions":2587,"interventions":2588},[63],[531],[472,398,533],{"nctId":633,"briefTitle":634,"status":81,"phases":2590,"primaryCompletion":636,"completion":615,"start":481,"enrollment":637,"conditions":2591,"interventions":2592},[62,63],[15],[440,398,640],{"trials":2594,"activeCount":73},[],{"trials":2596,"activeCount":73},[],{"trials":2598,"activeCount":73},[],{"intervention":545,"totalTrials":148,"cells":2600},{"EARLY_PHASE1":2601,"PHASE1":2603,"PHASE2":2605,"PHASE3":2617,"PHASE4":2619,"NA":2621},{"trials":2602,"activeCount":73},[],{"trials":2604,"activeCount":73},[],{"trials":2606,"activeCount":73},[2607,2611],{"nctId":535,"briefTitle":536,"status":81,"phases":2608,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":2609,"interventions":2610},[63],[543],[545,398,546],{"nctId":2612,"briefTitle":2613,"status":81,"phases":2614,"primaryCompletion":636,"completion":511,"start":540,"enrollment":2432,"conditions":2615,"interventions":2616},"NCT01033032","Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer",[62,63],[23],[545],{"trials":2618,"activeCount":73},[],{"trials":2620,"activeCount":73},[],{"trials":2622,"activeCount":73},[],{"intervention":138,"totalTrials":148,"cells":2624},{"EARLY_PHASE1":2625,"PHASE1":2627,"PHASE2":2629,"PHASE3":2639,"PHASE4":2641,"NA":2643},{"trials":2626,"activeCount":73},[],{"trials":2628,"activeCount":73},[],{"trials":2630,"activeCount":73},[2631,2635],{"nctId":1632,"briefTitle":1633,"status":81,"phases":2632,"primaryCompletion":500,"completion":490,"start":1635,"enrollment":595,"conditions":2633,"interventions":2634},[63],[597],[102,138,1638],{"nctId":128,"briefTitle":129,"status":81,"phases":2636,"primaryCompletion":131,"completion":96,"start":132,"enrollment":133,"conditions":2637,"interventions":2638},[62,63],[135],[137,102,138],{"trials":2640,"activeCount":73},[],{"trials":2642,"activeCount":73},[],{"trials":2644,"activeCount":73},[],{"intervention":2465,"totalTrials":148,"cells":2646},{"EARLY_PHASE1":2647,"PHASE1":2649,"PHASE2":2651,"PHASE3":2667,"PHASE4":2669,"NA":2671},{"trials":2648,"activeCount":73},[],{"trials":2650,"activeCount":73},[],{"trials":2652,"activeCount":73},[2653,2657],{"nctId":2458,"briefTitle":2459,"status":81,"phases":2654,"primaryCompletion":2461,"completion":2461,"start":1366,"enrollment":871,"conditions":2655,"interventions":2656},[62,63],[21],[2464,2465],{"nctId":2658,"briefTitle":2659,"status":81,"phases":2660,"primaryCompletion":2661,"completion":2661,"start":2662,"enrollment":626,"conditions":2663,"interventions":2665},"NCT02318784","Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers",[63],"2021-05-15","2015-07-15",[2664],"Neuroendocrine Cancer",[2666],"Carfilzomib",{"trials":2668,"activeCount":73},[],{"trials":2670,"activeCount":73},[],{"trials":2672,"activeCount":73},[],{"intervention":2674,"totalTrials":148,"cells":2675},"Cabazitaxel",{"EARLY_PHASE1":2676,"PHASE1":2678,"PHASE2":2680,"PHASE3":2694,"PHASE4":2696,"NA":2698},{"trials":2677,"activeCount":73},[],{"trials":2679,"activeCount":73},[],{"trials":2681,"activeCount":73},[2682,2690],{"nctId":2683,"briefTitle":2684,"status":1754,"phases":2685,"primaryCompletion":1857,"completion":1857,"start":665,"enrollment":73,"conditions":2686,"interventions":2688},"NCT02035124","Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel",[63],[2687],"Advanced Prostate Cancer",[2689,2674],"BKM 120",{"nctId":2114,"briefTitle":2115,"status":159,"phases":2691,"primaryCompletion":2117,"completion":1988,"start":2118,"enrollment":1445,"conditions":2692,"interventions":2693},[63],[2120],[2122,2123],{"trials":2695,"activeCount":73},[],{"trials":2697,"activeCount":73},[],{"trials":2699,"activeCount":73},[],{"intervention":1926,"totalTrials":148,"cells":2701},{"EARLY_PHASE1":2702,"PHASE1":2704,"PHASE2":2706,"PHASE3":2719,"PHASE4":2721,"NA":2723},{"trials":2703,"activeCount":73},[],{"trials":2705,"activeCount":73},[],{"trials":2707,"activeCount":73},[2708,2712],{"nctId":1920,"briefTitle":1921,"status":159,"phases":2709,"primaryCompletion":1923,"completion":424,"start":817,"enrollment":595,"conditions":2710,"interventions":2711},[63],[15],[1926,853],{"nctId":2713,"briefTitle":2714,"status":81,"phases":2715,"primaryCompletion":793,"completion":436,"start":897,"enrollment":595,"conditions":2716,"interventions":2717},"NCT00193544","Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma",[63],[21],[2718,1926],"Arsenic Trioxide",{"trials":2720,"activeCount":73},[],{"trials":2722,"activeCount":73},[],{"trials":2724,"activeCount":73},[],{"intervention":2718,"totalTrials":148,"cells":2726},{"EARLY_PHASE1":2727,"PHASE1":2729,"PHASE2":2731,"PHASE3":2743,"PHASE4":2745,"NA":2747},{"trials":2728,"activeCount":73},[],{"trials":2730,"activeCount":73},[],{"trials":2732,"activeCount":73},[2733,2739],{"nctId":2734,"briefTitle":2735,"status":81,"phases":2736,"primaryCompletion":1512,"completion":1512,"start":447,"enrollment":958,"conditions":2737,"interventions":2738},"NCT00193518","Arsenic Trioxide in Relapsed\u002FRefractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[63],[135,2182],[2718],{"nctId":2713,"briefTitle":2714,"status":81,"phases":2740,"primaryCompletion":793,"completion":436,"start":897,"enrollment":595,"conditions":2741,"interventions":2742},[63],[21],[2718,1926],{"trials":2744,"activeCount":73},[],{"trials":2746,"activeCount":73},[],{"trials":2748,"activeCount":73},[],{"intervention":2750,"totalTrials":148,"cells":2751},"OGX-427",{"EARLY_PHASE1":2752,"PHASE1":2754,"PHASE2":2756,"PHASE3":2775,"PHASE4":2777,"NA":2779},{"trials":2753,"activeCount":73},[],{"trials":2755,"activeCount":73},[],{"trials":2757,"activeCount":73},[2758,2766],{"nctId":2759,"briefTitle":2760,"status":81,"phases":2761,"primaryCompletion":2762,"completion":2762,"start":1353,"enrollment":2763,"conditions":2764,"interventions":2765},"NCT01844817","Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +\u002F- OGX-427 In Patients With Metastatic Pancreatic Cancer",[63],"2016-03",132,[949],[2750],{"nctId":2767,"briefTitle":2768,"status":81,"phases":2769,"primaryCompletion":2770,"completion":2770,"start":636,"enrollment":2771,"conditions":2772,"interventions":2774},"NCT01829113","Phase II Trial of Carboplatin and Pemetrexed +\u002F- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer",[63],"2017-04-19",155,[2773],"Non Squamous Non Small Cell Lung Cancer",[2750],{"trials":2776,"activeCount":73},[],{"trials":2778,"activeCount":73},[],{"trials":2780,"activeCount":73},[],{"intervention":115,"totalTrials":148,"cells":2782},{"EARLY_PHASE1":2783,"PHASE1":2785,"PHASE2":2787,"PHASE3":2797,"PHASE4":2799,"NA":2801},{"trials":2784,"activeCount":73},[],{"trials":2786,"activeCount":73},[],{"trials":2788,"activeCount":73},[2789,2793],{"nctId":105,"briefTitle":106,"status":81,"phases":2790,"primaryCompletion":108,"completion":109,"start":110,"enrollment":111,"conditions":2791,"interventions":2792},[63],[21],[114,69,115],{"nctId":1866,"briefTitle":1867,"status":81,"phases":2794,"primaryCompletion":720,"completion":1869,"start":1322,"enrollment":849,"conditions":2795,"interventions":2796},[63],[21],[1605,103,115],{"trials":2798,"activeCount":73},[],{"trials":2800,"activeCount":73},[],{"trials":2802,"activeCount":73},[],{"intervention":2332,"totalTrials":139,"cells":2804},{"EARLY_PHASE1":2805,"PHASE1":2807,"PHASE2":2809,"PHASE3":2815,"PHASE4":2817,"NA":2819},{"trials":2806,"activeCount":73},[],{"trials":2808,"activeCount":73},[],{"trials":2810,"activeCount":73},[2811],{"nctId":2322,"briefTitle":2323,"status":81,"phases":2812,"primaryCompletion":2325,"completion":2325,"start":2326,"enrollment":121,"conditions":2813,"interventions":2814},[63],[2328,986,2329,2330],[2332,2313,2333],{"trials":2816,"activeCount":73},[],{"trials":2818,"activeCount":73},[],{"trials":2820,"activeCount":73},[],{"intervention":2333,"totalTrials":139,"cells":2822},{"EARLY_PHASE1":2823,"PHASE1":2825,"PHASE2":2827,"PHASE3":2833,"PHASE4":2835,"NA":2837},{"trials":2824,"activeCount":73},[],{"trials":2826,"activeCount":73},[],{"trials":2828,"activeCount":73},[2829],{"nctId":2322,"briefTitle":2323,"status":81,"phases":2830,"primaryCompletion":2325,"completion":2325,"start":2326,"enrollment":121,"conditions":2831,"interventions":2832},[63],[2328,986,2329,2330],[2332,2313,2333],{"trials":2834,"activeCount":73},[],{"trials":2836,"activeCount":73},[],{"trials":2838,"activeCount":73},[],{"intervention":2840,"totalTrials":139,"cells":2841},"Itacitinib",{"EARLY_PHASE1":2842,"PHASE1":2844,"PHASE2":2846,"PHASE3":2857,"PHASE4":2859,"NA":2861},{"trials":2843,"activeCount":73},[],{"trials":2845,"activeCount":73},[],{"trials":2847,"activeCount":73},[2848],{"nctId":2849,"briefTitle":2850,"status":159,"phases":2851,"primaryCompletion":2852,"completion":2852,"start":2853,"enrollment":907,"conditions":2854,"interventions":2856},"NCT04200365","A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)",[63],"2023-09-07","2020-06-05",[2855],"Chronic Graft-versus-host-disease",[2840],{"trials":2858,"activeCount":73},[],{"trials":2860,"activeCount":73},[],{"trials":2862,"activeCount":73},[],{"intervention":1810,"totalTrials":139,"cells":2864},{"EARLY_PHASE1":2865,"PHASE1":2867,"PHASE2":2869,"PHASE3":2875,"PHASE4":2877,"NA":2879},{"trials":2866,"activeCount":73},[],{"trials":2868,"activeCount":73},[],{"trials":2870,"activeCount":73},[2871],{"nctId":1803,"briefTitle":1804,"status":81,"phases":2872,"primaryCompletion":1806,"completion":1806,"start":1807,"enrollment":1538,"conditions":2873,"interventions":2874},[63],[15],[650,1810,1811,1387,1386,1812,1813],{"trials":2876,"activeCount":73},[],{"trials":2878,"activeCount":73},[],{"trials":2880,"activeCount":73},[],{"intervention":1811,"totalTrials":139,"cells":2882},{"EARLY_PHASE1":2883,"PHASE1":2885,"PHASE2":2887,"PHASE3":2893,"PHASE4":2895,"NA":2897},{"trials":2884,"activeCount":73},[],{"trials":2886,"activeCount":73},[],{"trials":2888,"activeCount":73},[2889],{"nctId":1803,"briefTitle":1804,"status":81,"phases":2890,"primaryCompletion":1806,"completion":1806,"start":1807,"enrollment":1538,"conditions":2891,"interventions":2892},[63],[15],[650,1810,1811,1387,1386,1812,1813],{"trials":2894,"activeCount":73},[],{"trials":2896,"activeCount":73},[],{"trials":2898,"activeCount":73},[],{"intervention":1812,"totalTrials":139,"cells":2900},{"EARLY_PHASE1":2901,"PHASE1":2903,"PHASE2":2905,"PHASE3":2911,"PHASE4":2913,"NA":2915},{"trials":2902,"activeCount":73},[],{"trials":2904,"activeCount":73},[],{"trials":2906,"activeCount":73},[2907],{"nctId":1803,"briefTitle":1804,"status":81,"phases":2908,"primaryCompletion":1806,"completion":1806,"start":1807,"enrollment":1538,"conditions":2909,"interventions":2910},[63],[15],[650,1810,1811,1387,1386,1812,1813],{"trials":2912,"activeCount":73},[],{"trials":2914,"activeCount":73},[],{"trials":2916,"activeCount":73},[],{"intervention":1813,"totalTrials":139,"cells":2918},{"EARLY_PHASE1":2919,"PHASE1":2921,"PHASE2":2923,"PHASE3":2929,"PHASE4":2931,"NA":2933},{"trials":2920,"activeCount":73},[],{"trials":2922,"activeCount":73},[],{"trials":2924,"activeCount":73},[2925],{"nctId":1803,"briefTitle":1804,"status":81,"phases":2926,"primaryCompletion":1806,"completion":1806,"start":1807,"enrollment":1538,"conditions":2927,"interventions":2928},[63],[15],[650,1810,1811,1387,1386,1812,1813],{"trials":2930,"activeCount":73},[],{"trials":2932,"activeCount":73},[],{"trials":2934,"activeCount":73},[],{"intervention":1317,"totalTrials":139,"cells":2936},{"EARLY_PHASE1":2937,"PHASE1":2939,"PHASE2":2941,"PHASE3":2947,"PHASE4":2949,"NA":2951},{"trials":2938,"activeCount":73},[],{"trials":2940,"activeCount":73},[],{"trials":2942,"activeCount":73},[2943],{"nctId":1309,"briefTitle":1310,"status":81,"phases":2944,"primaryCompletion":1312,"completion":161,"start":1313,"enrollment":1314,"conditions":2945,"interventions":2946},[63],[1296],[1317,485],{"trials":2948,"activeCount":73},[],{"trials":2950,"activeCount":73},[],{"trials":2952,"activeCount":73},[],{"intervention":1327,"totalTrials":139,"cells":2954},{"EARLY_PHASE1":2955,"PHASE1":2957,"PHASE2":2959,"PHASE3":2965,"PHASE4":2967,"NA":2969},{"trials":2956,"activeCount":73},[],{"trials":2958,"activeCount":73},[],{"trials":2960,"activeCount":73},[2961],{"nctId":1319,"briefTitle":1320,"status":81,"phases":2962,"primaryCompletion":1032,"completion":720,"start":1322,"enrollment":1323,"conditions":2963,"interventions":2964},[63],[503],[485,1326,1327],{"trials":2966,"activeCount":73},[],{"trials":2968,"activeCount":73},[],{"trials":2970,"activeCount":73},[],{"intervention":2972,"totalTrials":139,"cells":2973},"Docetaxel\u002FCarboplatin\u002FBevacizumab\u002FErlotinib",{"EARLY_PHASE1":2974,"PHASE1":2976,"PHASE2":2978,"PHASE3":2988,"PHASE4":2990,"NA":2992},{"trials":2975,"activeCount":73},[],{"trials":2977,"activeCount":73},[],{"trials":2979,"activeCount":73},[2980],{"nctId":2981,"briefTitle":2982,"status":81,"phases":2983,"primaryCompletion":636,"completion":1031,"start":694,"enrollment":2984,"conditions":2985,"interventions":2986},"NCT00621049","Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC",[63],112,[26],[2972,2987],"Docetaxel\u002FCarboplatin",{"trials":2989,"activeCount":73},[],{"trials":2991,"activeCount":73},[],{"trials":2993,"activeCount":73},[],{"intervention":2987,"totalTrials":139,"cells":2995},{"EARLY_PHASE1":2996,"PHASE1":2998,"PHASE2":3000,"PHASE3":3006,"PHASE4":3008,"NA":3010},{"trials":2997,"activeCount":73},[],{"trials":2999,"activeCount":73},[],{"trials":3001,"activeCount":73},[3002],{"nctId":2981,"briefTitle":2982,"status":81,"phases":3003,"primaryCompletion":636,"completion":1031,"start":694,"enrollment":2984,"conditions":3004,"interventions":3005},[63],[26],[2972,2987],{"trials":3007,"activeCount":73},[],{"trials":3009,"activeCount":73},[],{"trials":3011,"activeCount":73},[],{"intervention":1860,"totalTrials":139,"cells":3013},{"EARLY_PHASE1":3014,"PHASE1":3016,"PHASE2":3018,"PHASE3":3024,"PHASE4":3026,"NA":3028},{"trials":3015,"activeCount":73},[],{"trials":3017,"activeCount":73},[],{"trials":3019,"activeCount":73},[3020],{"nctId":1853,"briefTitle":1854,"status":159,"phases":3021,"primaryCompletion":1856,"completion":1856,"start":1857,"enrollment":1010,"conditions":3022,"interventions":3023},[63],[21],[1860,103],{"trials":3025,"activeCount":73},[],{"trials":3027,"activeCount":73},[],{"trials":3029,"activeCount":73},[],{"intervention":3031,"totalTrials":139,"cells":3032},"CPX-351",{"EARLY_PHASE1":3033,"PHASE1":3035,"PHASE2":3037,"PHASE3":3047,"PHASE4":3049,"NA":3051},{"trials":3034,"activeCount":73},[],{"trials":3036,"activeCount":73},[],{"trials":3038,"activeCount":73},[3039],{"nctId":3040,"briefTitle":3041,"status":159,"phases":3042,"primaryCompletion":2552,"completion":2552,"start":3043,"enrollment":139,"conditions":3044,"interventions":3045},"NCT04209725","A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia",[63],"2020-06-03",[2555],[3031,3046],"Quizartinib",{"trials":3048,"activeCount":73},[],{"trials":3050,"activeCount":73},[],{"trials":3052,"activeCount":73},[],{"intervention":3046,"totalTrials":139,"cells":3054},{"EARLY_PHASE1":3055,"PHASE1":3057,"PHASE2":3059,"PHASE3":3065,"PHASE4":3067,"NA":3069},{"trials":3056,"activeCount":73},[],{"trials":3058,"activeCount":73},[],{"trials":3060,"activeCount":73},[3061],{"nctId":3040,"briefTitle":3041,"status":159,"phases":3062,"primaryCompletion":2552,"completion":2552,"start":3043,"enrollment":139,"conditions":3063,"interventions":3064},[63],[2555],[3031,3046],{"trials":3066,"activeCount":73},[],{"trials":3068,"activeCount":73},[],{"trials":3070,"activeCount":73},[],{"intervention":3072,"totalTrials":139,"cells":3073},"ZD1839",{"EARLY_PHASE1":3074,"PHASE1":3076,"PHASE2":3078,"PHASE3":3087,"PHASE4":3089,"NA":3091},{"trials":3075,"activeCount":73},[],{"trials":3077,"activeCount":73},[],{"trials":3079,"activeCount":73},[3080],{"nctId":3081,"briefTitle":3082,"status":81,"phases":3083,"primaryCompletion":858,"completion":973,"start":3084,"enrollment":312,"conditions":3085,"interventions":3086},"NCT00193336","Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer",[63],"2003-03",[18],[3072],{"trials":3088,"activeCount":73},[],{"trials":3090,"activeCount":73},[],{"trials":3092,"activeCount":73},[],{"intervention":3094,"totalTrials":139,"cells":3095},"Lanreotide",{"EARLY_PHASE1":3096,"PHASE1":3098,"PHASE2":3100,"PHASE3":3114,"PHASE4":3116,"NA":3118},{"trials":3097,"activeCount":73},[],{"trials":3099,"activeCount":73},[],{"trials":3101,"activeCount":73},[3102],{"nctId":3103,"briefTitle":3104,"status":159,"phases":3105,"primaryCompletion":3106,"completion":3107,"start":3108,"enrollment":27,"conditions":3109,"interventions":3113},"NCT02859064","Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres",[63],"2022-05-27","2022-06-10","2017-07-28",[3110,3111,3112],"Neuroendocrine Tumors","Gastrointestinal Neoplasms","Carcinoid Tumors",[3094],{"trials":3115,"activeCount":73},[],{"trials":3117,"activeCount":73},[],{"trials":3119,"activeCount":73},[],{"intervention":811,"totalTrials":139,"cells":3121},{"EARLY_PHASE1":3122,"PHASE1":3124,"PHASE2":3126,"PHASE3":3132,"PHASE4":3134,"NA":3136},{"trials":3123,"activeCount":73},[],{"trials":3125,"activeCount":73},[],{"trials":3127,"activeCount":73},[3128],{"nctId":804,"briefTitle":805,"status":81,"phases":3129,"primaryCompletion":446,"completion":606,"start":807,"enrollment":808,"conditions":3130,"interventions":3131},[63],[15],[811,451],{"trials":3133,"activeCount":73},[],{"trials":3135,"activeCount":73},[],{"trials":3137,"activeCount":73},[],{"intervention":3139,"totalTrials":139,"cells":3140},"Acalabrutinib",{"EARLY_PHASE1":3141,"PHASE1":3143,"PHASE2":3145,"PHASE3":3155,"PHASE4":3157,"NA":3159},{"trials":3142,"activeCount":73},[],{"trials":3144,"activeCount":73},[],{"trials":3146,"activeCount":73},[3147],{"nctId":3148,"briefTitle":3149,"status":81,"phases":3150,"primaryCompletion":3151,"completion":3151,"start":3152,"enrollment":907,"conditions":3153,"interventions":3154},"NCT04402138","Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma",[63],"2024-04-05","2020-08-07",[100],[3139],{"trials":3156,"activeCount":73},[],{"trials":3158,"activeCount":73},[],{"trials":3160,"activeCount":73},[],{"intervention":1046,"totalTrials":139,"cells":3162},{"EARLY_PHASE1":3163,"PHASE1":3165,"PHASE2":3167,"PHASE3":3173,"PHASE4":3175,"NA":3177},{"trials":3164,"activeCount":73},[],{"trials":3166,"activeCount":73},[],{"trials":3168,"activeCount":73},[3169],{"nctId":1040,"briefTitle":1041,"status":81,"phases":3170,"primaryCompletion":423,"completion":423,"start":1043,"enrollment":425,"conditions":3171,"interventions":3172},[63],[33],[1046,485,576,576,1026,852],{"trials":3174,"activeCount":73},[],{"trials":3176,"activeCount":73},[],{"trials":3178,"activeCount":73},[],{"intervention":3180,"totalTrials":139,"cells":3181},"Aflibercept",{"EARLY_PHASE1":3182,"PHASE1":3184,"PHASE2":3186,"PHASE3":3196,"PHASE4":3198,"NA":3200},{"trials":3183,"activeCount":73},[],{"trials":3185,"activeCount":73},[],{"trials":3187,"activeCount":73},[3188],{"nctId":3189,"briefTitle":3190,"status":81,"phases":3191,"primaryCompletion":721,"completion":721,"start":3192,"enrollment":98,"conditions":3193,"interventions":3194},"NCT01749956","5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II\u002FIII Rectal Cancer",[63],"2013-01",[315],[3180,3195],"FOLFOX6",{"trials":3197,"activeCount":73},[],{"trials":3199,"activeCount":73},[],{"trials":3201,"activeCount":73},[],{"intervention":3195,"totalTrials":139,"cells":3203},{"EARLY_PHASE1":3204,"PHASE1":3206,"PHASE2":3208,"PHASE3":3214,"PHASE4":3216,"NA":3218},{"trials":3205,"activeCount":73},[],{"trials":3207,"activeCount":73},[],{"trials":3209,"activeCount":73},[3210],{"nctId":3189,"briefTitle":3190,"status":81,"phases":3211,"primaryCompletion":721,"completion":721,"start":3192,"enrollment":98,"conditions":3212,"interventions":3213},[63],[315],[3180,3195],{"trials":3215,"activeCount":73},[],{"trials":3217,"activeCount":73},[],{"trials":3219,"activeCount":73},[],{"intervention":546,"totalTrials":139,"cells":3221},{"EARLY_PHASE1":3222,"PHASE1":3224,"PHASE2":3226,"PHASE3":3232,"PHASE4":3234,"NA":3236},{"trials":3223,"activeCount":73},[],{"trials":3225,"activeCount":73},[],{"trials":3227,"activeCount":73},[3228],{"nctId":535,"briefTitle":536,"status":81,"phases":3229,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":3230,"interventions":3231},[63],[543],[545,398,546],{"trials":3233,"activeCount":73},[],{"trials":3235,"activeCount":73},[],{"trials":3237,"activeCount":73},[],{"intervention":1628,"totalTrials":139,"cells":3239},{"EARLY_PHASE1":3240,"PHASE1":3242,"PHASE2":3244,"PHASE3":3250,"PHASE4":3252,"NA":3254},{"trials":3241,"activeCount":73},[],{"trials":3243,"activeCount":73},[],{"trials":3245,"activeCount":73},[3246],{"nctId":1620,"briefTitle":1621,"status":81,"phases":3247,"primaryCompletion":1623,"completion":616,"start":1624,"enrollment":1625,"conditions":3248,"interventions":3249},[63],[597],[844,1628,1629,1630,102],{"trials":3251,"activeCount":73},[],{"trials":3253,"activeCount":73},[],{"trials":3255,"activeCount":73},[],{"intervention":1629,"totalTrials":139,"cells":3257},{"EARLY_PHASE1":3258,"PHASE1":3260,"PHASE2":3262,"PHASE3":3268,"PHASE4":3270,"NA":3272},{"trials":3259,"activeCount":73},[],{"trials":3261,"activeCount":73},[],{"trials":3263,"activeCount":73},[3264],{"nctId":1620,"briefTitle":1621,"status":81,"phases":3265,"primaryCompletion":1623,"completion":616,"start":1624,"enrollment":1625,"conditions":3266,"interventions":3267},[63],[597],[844,1628,1629,1630,102],{"trials":3269,"activeCount":73},[],{"trials":3271,"activeCount":73},[],{"trials":3273,"activeCount":73},[],{"intervention":1630,"totalTrials":139,"cells":3275},{"EARLY_PHASE1":3276,"PHASE1":3278,"PHASE2":3280,"PHASE3":3286,"PHASE4":3288,"NA":3290},{"trials":3277,"activeCount":73},[],{"trials":3279,"activeCount":73},[],{"trials":3281,"activeCount":73},[3282],{"nctId":1620,"briefTitle":1621,"status":81,"phases":3283,"primaryCompletion":1623,"completion":616,"start":1624,"enrollment":1625,"conditions":3284,"interventions":3285},[63],[597],[844,1628,1629,1630,102],{"trials":3287,"activeCount":73},[],{"trials":3289,"activeCount":73},[],{"trials":3291,"activeCount":73},[],{"intervention":1638,"totalTrials":139,"cells":3293},{"EARLY_PHASE1":3294,"PHASE1":3296,"PHASE2":3298,"PHASE3":3304,"PHASE4":3306,"NA":3308},{"trials":3295,"activeCount":73},[],{"trials":3297,"activeCount":73},[],{"trials":3299,"activeCount":73},[3300],{"nctId":1632,"briefTitle":1633,"status":81,"phases":3301,"primaryCompletion":500,"completion":490,"start":1635,"enrollment":595,"conditions":3302,"interventions":3303},[63],[597],[102,138,1638],{"trials":3305,"activeCount":73},[],{"trials":3307,"activeCount":73},[],{"trials":3309,"activeCount":73},[],{"intervention":2209,"totalTrials":139,"cells":3311},{"EARLY_PHASE1":3312,"PHASE1":3314,"PHASE2":3316,"PHASE3":3322,"PHASE4":3324,"NA":3326},{"trials":3313,"activeCount":73},[],{"trials":3315,"activeCount":73},[],{"trials":3317,"activeCount":73},[3318],{"nctId":2203,"briefTitle":2204,"status":1754,"phases":3319,"enrollment":73,"conditions":3320,"interventions":3321},[63],[2207],[1903,2209],{"trials":3323,"activeCount":73},[],{"trials":3325,"activeCount":73},[],{"trials":3327,"activeCount":73},[],{"intervention":2689,"totalTrials":139,"cells":3329},{"EARLY_PHASE1":3330,"PHASE1":3332,"PHASE2":3334,"PHASE3":3340,"PHASE4":3342,"NA":3344},{"trials":3331,"activeCount":73},[],{"trials":3333,"activeCount":73},[],{"trials":3335,"activeCount":73},[3336],{"nctId":2683,"briefTitle":2684,"status":1754,"phases":3337,"primaryCompletion":1857,"completion":1857,"start":665,"enrollment":73,"conditions":3338,"interventions":3339},[63],[2687],[2689,2674],{"trials":3341,"activeCount":73},[],{"trials":3343,"activeCount":73},[],{"trials":3345,"activeCount":73},[],{"intervention":3347,"totalTrials":139,"cells":3348},"Rituximab plus Temozolomide",{"EARLY_PHASE1":3349,"PHASE1":3351,"PHASE2":3353,"PHASE3":3362,"PHASE4":3364,"NA":3366},{"trials":3350,"activeCount":73},[],{"trials":3352,"activeCount":73},[],{"trials":3354,"activeCount":73},[3355],{"nctId":3356,"briefTitle":3357,"status":159,"phases":3358,"primaryCompletion":2117,"completion":2117,"start":479,"enrollment":148,"conditions":3359,"interventions":3361},"NCT02113007","Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma",[63],[3360],"Primary Central Nervous System Lymphoma",[3347],{"trials":3363,"activeCount":73},[],{"trials":3365,"activeCount":73},[],{"trials":3367,"activeCount":73},[],{"intervention":3369,"totalTrials":139,"cells":3370},"Orteronel",{"EARLY_PHASE1":3371,"PHASE1":3373,"PHASE2":3375,"PHASE3":3384,"PHASE4":3386,"NA":3388},{"trials":3372,"activeCount":73},[],{"trials":3374,"activeCount":73},[],{"trials":3376,"activeCount":73},[3377],{"nctId":3378,"briefTitle":3379,"status":81,"phases":3380,"primaryCompletion":3381,"completion":3381,"start":161,"enrollment":617,"conditions":3382,"interventions":3383},"NCT01990209","Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)",[63],"2021-05-01",[23],[3369],{"trials":3385,"activeCount":73},[],{"trials":3387,"activeCount":73},[],{"trials":3389,"activeCount":73},[],{"intervention":1646,"totalTrials":139,"cells":3391},{"EARLY_PHASE1":3392,"PHASE1":3394,"PHASE2":3396,"PHASE3":3402,"PHASE4":3404,"NA":3406},{"trials":3393,"activeCount":73},[],{"trials":3395,"activeCount":73},[],{"trials":3397,"activeCount":73},[3398],{"nctId":1640,"briefTitle":1641,"status":81,"phases":3399,"primaryCompletion":447,"completion":436,"start":1643,"enrollment":595,"conditions":3400,"interventions":3401},[63],[597],[102,1646,1647,1648],{"trials":3403,"activeCount":73},[],{"trials":3405,"activeCount":73},[],{"trials":3407,"activeCount":73},[],{"intervention":1647,"totalTrials":139,"cells":3409},{"EARLY_PHASE1":3410,"PHASE1":3412,"PHASE2":3414,"PHASE3":3420,"PHASE4":3422,"NA":3424},{"trials":3411,"activeCount":73},[],{"trials":3413,"activeCount":73},[],{"trials":3415,"activeCount":73},[3416],{"nctId":1640,"briefTitle":1641,"status":81,"phases":3417,"primaryCompletion":447,"completion":436,"start":1643,"enrollment":595,"conditions":3418,"interventions":3419},[63],[597],[102,1646,1647,1648],{"trials":3421,"activeCount":73},[],{"trials":3423,"activeCount":73},[],{"trials":3425,"activeCount":73},[],{"intervention":1648,"totalTrials":139,"cells":3427},{"EARLY_PHASE1":3428,"PHASE1":3430,"PHASE2":3432,"PHASE3":3438,"PHASE4":3440,"NA":3442},{"trials":3429,"activeCount":73},[],{"trials":3431,"activeCount":73},[],{"trials":3433,"activeCount":73},[3434],{"nctId":1640,"briefTitle":1641,"status":81,"phases":3435,"primaryCompletion":447,"completion":436,"start":1643,"enrollment":595,"conditions":3436,"interventions":3437},[63],[597],[102,1646,1647,1648],{"trials":3439,"activeCount":73},[],{"trials":3441,"activeCount":73},[],{"trials":3443,"activeCount":73},[],{"intervention":3445,"totalTrials":139,"cells":3446},"U3-1402",{"EARLY_PHASE1":3447,"PHASE1":3449,"PHASE2":3451,"PHASE3":3462,"PHASE4":3464,"NA":3466},{"trials":3448,"activeCount":73},[],{"trials":3450,"activeCount":73},[],{"trials":3452,"activeCount":73},[3453],{"nctId":3454,"briefTitle":3455,"status":81,"phases":3456,"primaryCompletion":3457,"completion":3457,"start":1784,"enrollment":3458,"conditions":3459,"interventions":3461},"NCT04699630","A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer",[63],"2025-04-09",121,[23,3460],"Locally Advanced Breast Cancer",[3445],{"trials":3463,"activeCount":73},[],{"trials":3465,"activeCount":73},[],{"trials":3467,"activeCount":73},[],{"intervention":599,"totalTrials":139,"cells":3469},{"EARLY_PHASE1":3470,"PHASE1":3472,"PHASE2":3474,"PHASE3":3480,"PHASE4":3482,"NA":3484},{"trials":3471,"activeCount":73},[],{"trials":3473,"activeCount":73},[],{"trials":3475,"activeCount":73},[3476],{"nctId":590,"briefTitle":591,"status":81,"phases":3477,"primaryCompletion":593,"completion":593,"start":594,"enrollment":595,"conditions":3478,"interventions":3479},[63],[597],[599,398,505,102,600],{"trials":3481,"activeCount":73},[],{"trials":3483,"activeCount":73},[],{"trials":3485,"activeCount":73},[],{"intervention":600,"totalTrials":139,"cells":3487},{"EARLY_PHASE1":3488,"PHASE1":3490,"PHASE2":3492,"PHASE3":3498,"PHASE4":3500,"NA":3502},{"trials":3489,"activeCount":73},[],{"trials":3491,"activeCount":73},[],{"trials":3493,"activeCount":73},[3494],{"nctId":590,"briefTitle":591,"status":81,"phases":3495,"primaryCompletion":593,"completion":593,"start":594,"enrollment":595,"conditions":3496,"interventions":3497},[63],[597],[599,398,505,102,600],{"trials":3499,"activeCount":73},[],{"trials":3501,"activeCount":73},[],{"trials":3503,"activeCount":73},[],{"intervention":1421,"totalTrials":139,"cells":3505},{"EARLY_PHASE1":3506,"PHASE1":3508,"PHASE2":3510,"PHASE3":3516,"PHASE4":3518,"NA":3520},{"trials":3507,"activeCount":73},[],{"trials":3509,"activeCount":73},[],{"trials":3511,"activeCount":73},[3512],{"nctId":1413,"briefTitle":1414,"status":81,"phases":3513,"primaryCompletion":1416,"completion":1417,"start":1366,"enrollment":1418,"conditions":3514,"interventions":3515},[62,63],[1245],[485,1421],{"trials":3517,"activeCount":73},[],{"trials":3519,"activeCount":73},[],{"trials":3521,"activeCount":73},[],{"intervention":3523,"totalTrials":139,"cells":3524},"AUY922",{"EARLY_PHASE1":3525,"PHASE1":3527,"PHASE2":3529,"PHASE3":3538,"PHASE4":3540,"NA":3542},{"trials":3526,"activeCount":73},[],{"trials":3528,"activeCount":73},[],{"trials":3530,"activeCount":73},[3531],{"nctId":3532,"briefTitle":3533,"status":81,"phases":3534,"primaryCompletion":1032,"completion":1032,"start":1366,"enrollment":16,"conditions":3535,"interventions":3537},"NCT01404650","Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor",[63],[3536],"Gastrointestinal Stromal Tumor",[3523],{"trials":3539,"activeCount":73},[],{"trials":3541,"activeCount":73},[],{"trials":3543,"activeCount":73},[],{"intervention":3545,"totalTrials":139,"cells":3546},"Erlotinib + Sorafenib",{"EARLY_PHASE1":3547,"PHASE1":3549,"PHASE2":3551,"PHASE3":3561,"PHASE4":3563,"NA":3565},{"trials":3548,"activeCount":73},[],{"trials":3550,"activeCount":73},[],{"trials":3552,"activeCount":73},[3553],{"nctId":3554,"briefTitle":3555,"status":81,"phases":3556,"primaryCompletion":85,"completion":85,"start":581,"enrollment":3557,"conditions":3558,"interventions":3559},"NCT00600015","Sorafenib\u002FErlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)",[63],166,[26],[3545,3560],"Erlotinib + Placebo",{"trials":3562,"activeCount":73},[],{"trials":3564,"activeCount":73},[],{"trials":3566,"activeCount":73},[],{"intervention":3560,"totalTrials":139,"cells":3568},{"EARLY_PHASE1":3569,"PHASE1":3571,"PHASE2":3573,"PHASE3":3579,"PHASE4":3581,"NA":3583},{"trials":3570,"activeCount":73},[],{"trials":3572,"activeCount":73},[],{"trials":3574,"activeCount":73},[3575],{"nctId":3554,"briefTitle":3555,"status":81,"phases":3576,"primaryCompletion":85,"completion":85,"start":581,"enrollment":3557,"conditions":3577,"interventions":3578},[63],[26],[3545,3560],{"trials":3580,"activeCount":73},[],{"trials":3582,"activeCount":73},[],{"trials":3584,"activeCount":73},[],{"intervention":114,"totalTrials":139,"cells":3586},{"EARLY_PHASE1":3587,"PHASE1":3589,"PHASE2":3591,"PHASE3":3597,"PHASE4":3599,"NA":3601},{"trials":3588,"activeCount":73},[],{"trials":3590,"activeCount":73},[],{"trials":3592,"activeCount":73},[3593],{"nctId":105,"briefTitle":106,"status":81,"phases":3594,"primaryCompletion":108,"completion":109,"start":110,"enrollment":111,"conditions":3595,"interventions":3596},[63],[21],[114,69,115],{"trials":3598,"activeCount":73},[],{"trials":3600,"activeCount":73},[],{"trials":3602,"activeCount":73},[],{"intervention":3604,"totalTrials":139,"cells":3605},"BKM120 and Erlotinib",{"EARLY_PHASE1":3606,"PHASE1":3608,"PHASE2":3610,"PHASE3":3620,"PHASE4":3622,"NA":3624},{"trials":3607,"activeCount":73},[],{"trials":3609,"activeCount":73},[],{"trials":3611,"activeCount":73},[3612],{"nctId":3613,"briefTitle":3614,"status":81,"phases":3615,"primaryCompletion":3616,"completion":3617,"start":161,"enrollment":529,"conditions":3618,"interventions":3619},"NCT01487265","Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib",[63],"2016-05-31","2017-12-11",[31],[3604],{"trials":3621,"activeCount":73},[],{"trials":3623,"activeCount":73},[],{"trials":3625,"activeCount":73},[],{"intervention":3627,"totalTrials":139,"cells":3628},"Atezolizumab",{"EARLY_PHASE1":3629,"PHASE1":3631,"PHASE2":3633,"PHASE3":3646,"PHASE4":3648,"NA":3650},{"trials":3630,"activeCount":73},[],{"trials":3632,"activeCount":73},[],{"trials":3634,"activeCount":73},[3635],{"nctId":3636,"briefTitle":3637,"status":81,"phases":3638,"primaryCompletion":3639,"completion":3639,"start":3640,"enrollment":722,"conditions":3641,"interventions":3643},"NCT03977467","Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor",[63],"2024-08-09","2019-08-30",[26,3642],"Solid Tumor",[3627,3644,3645],"Standard of Care Chemotherapy","Tiragolumab",{"trials":3647,"activeCount":73},[],{"trials":3649,"activeCount":73},[],{"trials":3651,"activeCount":73},[],{"intervention":3644,"totalTrials":139,"cells":3653},{"EARLY_PHASE1":3654,"PHASE1":3656,"PHASE2":3658,"PHASE3":3664,"PHASE4":3666,"NA":3668},{"trials":3655,"activeCount":73},[],{"trials":3657,"activeCount":73},[],{"trials":3659,"activeCount":73},[3660],{"nctId":3636,"briefTitle":3637,"status":81,"phases":3661,"primaryCompletion":3639,"completion":3639,"start":3640,"enrollment":722,"conditions":3662,"interventions":3663},[63],[26,3642],[3627,3644,3645],{"trials":3665,"activeCount":73},[],{"trials":3667,"activeCount":73},[],{"trials":3669,"activeCount":73},[],{"intervention":3645,"totalTrials":139,"cells":3671},{"EARLY_PHASE1":3672,"PHASE1":3674,"PHASE2":3676,"PHASE3":3682,"PHASE4":3684,"NA":3686},{"trials":3673,"activeCount":73},[],{"trials":3675,"activeCount":73},[],{"trials":3677,"activeCount":73},[3678],{"nctId":3636,"briefTitle":3637,"status":81,"phases":3679,"primaryCompletion":3639,"completion":3639,"start":3640,"enrollment":722,"conditions":3680,"interventions":3681},[63],[26,3642],[3627,3644,3645],{"trials":3683,"activeCount":73},[],{"trials":3685,"activeCount":73},[],{"trials":3687,"activeCount":73},[],{"intervention":688,"totalTrials":139,"cells":3689},{"EARLY_PHASE1":3690,"PHASE1":3692,"PHASE2":3694,"PHASE3":3700,"PHASE4":3702,"NA":3704},{"trials":3691,"activeCount":73},[],{"trials":3693,"activeCount":73},[],{"trials":3695,"activeCount":73},[3696],{"nctId":682,"briefTitle":683,"status":81,"phases":3697,"primaryCompletion":656,"completion":436,"start":594,"enrollment":657,"conditions":3698,"interventions":3699},[63],[686],[688,451,398,689],{"trials":3701,"activeCount":73},[],{"trials":3703,"activeCount":73},[],{"trials":3705,"activeCount":73},[],{"intervention":689,"totalTrials":139,"cells":3707},{"EARLY_PHASE1":3708,"PHASE1":3710,"PHASE2":3712,"PHASE3":3718,"PHASE4":3720,"NA":3722},{"trials":3709,"activeCount":73},[],{"trials":3711,"activeCount":73},[],{"trials":3713,"activeCount":73},[3714],{"nctId":682,"briefTitle":683,"status":81,"phases":3715,"primaryCompletion":656,"completion":436,"start":594,"enrollment":657,"conditions":3716,"interventions":3717},[63],[686],[688,451,398,689],{"trials":3719,"activeCount":73},[],{"trials":3721,"activeCount":73},[],{"trials":3723,"activeCount":73},[],{"intervention":951,"totalTrials":139,"cells":3725},{"EARLY_PHASE1":3726,"PHASE1":3728,"PHASE2":3730,"PHASE3":3736,"PHASE4":3738,"NA":3740},{"trials":3727,"activeCount":73},[],{"trials":3729,"activeCount":73},[],{"trials":3731,"activeCount":73},[3732],{"nctId":942,"briefTitle":943,"status":81,"phases":3733,"primaryCompletion":446,"completion":945,"start":946,"enrollment":947,"conditions":3734,"interventions":3735},[62,63],[949],[951,90],{"trials":3737,"activeCount":73},[],{"trials":3739,"activeCount":73},[],{"trials":3741,"activeCount":73},[],{"intervention":2034,"totalTrials":139,"cells":3743},{"EARLY_PHASE1":3744,"PHASE1":3746,"PHASE2":3748,"PHASE3":3754,"PHASE4":3756,"NA":3758},{"trials":3745,"activeCount":73},[],{"trials":3747,"activeCount":73},[],{"trials":3749,"activeCount":73},[3750],{"nctId":2026,"briefTitle":2027,"status":81,"phases":3751,"primaryCompletion":2029,"completion":2029,"start":2030,"enrollment":1243,"conditions":3752,"interventions":3753},[63],[2032],[990,2034],{"trials":3755,"activeCount":73},[],{"trials":3757,"activeCount":73},[],{"trials":3759,"activeCount":73},[],{"intervention":1762,"totalTrials":139,"cells":3761},{"EARLY_PHASE1":3762,"PHASE1":3764,"PHASE2":3766,"PHASE3":3772,"PHASE4":3774,"NA":3776},{"trials":3763,"activeCount":73},[],{"trials":3765,"activeCount":73},[],{"trials":3767,"activeCount":73},[3768],{"nctId":1752,"briefTitle":1753,"status":1754,"phases":3769,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":73,"conditions":3770,"interventions":3771},[63],[18,1760],[1762,1763,429],{"trials":3773,"activeCount":73},[],{"trials":3775,"activeCount":73},[],{"trials":3777,"activeCount":73},[],{"intervention":1763,"totalTrials":139,"cells":3779},{"EARLY_PHASE1":3780,"PHASE1":3782,"PHASE2":3784,"PHASE3":3790,"PHASE4":3792,"NA":3794},{"trials":3781,"activeCount":73},[],{"trials":3783,"activeCount":73},[],{"trials":3785,"activeCount":73},[3786],{"nctId":1752,"briefTitle":1753,"status":1754,"phases":3787,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":73,"conditions":3788,"interventions":3789},[63],[18,1760],[1762,1763,429],{"trials":3791,"activeCount":73},[],{"trials":3793,"activeCount":73},[],{"trials":3795,"activeCount":73},[],{"intervention":3797,"totalTrials":139,"cells":3798},"MLN9708",{"EARLY_PHASE1":3799,"PHASE1":3801,"PHASE2":3803,"PHASE3":3812,"PHASE4":3814,"NA":3816},{"trials":3800,"activeCount":73},[],{"trials":3802,"activeCount":73},[],{"trials":3804,"activeCount":73},[3805],{"nctId":3806,"briefTitle":3807,"status":81,"phases":3808,"primaryCompletion":3809,"completion":3809,"start":615,"enrollment":24,"conditions":3810,"interventions":3811},"NCT02168101","Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma",[63],"2019-02-01",[21],[3797],{"trials":3813,"activeCount":73},[],{"trials":3815,"activeCount":73},[],{"trials":3817,"activeCount":73},[],{"intervention":3819,"totalTrials":139,"cells":3820},"nab paclitaxel",{"EARLY_PHASE1":3821,"PHASE1":3823,"PHASE2":3825,"PHASE3":3833,"PHASE4":3835,"NA":3837},{"trials":3822,"activeCount":73},[],{"trials":3824,"activeCount":73},[],{"trials":3826,"activeCount":73},[3827],{"nctId":3828,"briefTitle":3829,"status":81,"phases":3830,"primaryCompletion":561,"completion":711,"start":490,"enrollment":1314,"conditions":3831,"interventions":3832},"NCT00629499","Nanoparticle Albumin-Bound (Nab) Paclitaxel\u002FCyclophosphamide in Early-Stage Breast Cancer",[63],[15],[3819,844,515],{"trials":3834,"activeCount":73},[],{"trials":3836,"activeCount":73},[],{"trials":3838,"activeCount":73},[],{"intervention":3840,"totalTrials":139,"cells":3841},"Tivantinib",{"EARLY_PHASE1":3842,"PHASE1":3844,"PHASE2":3846,"PHASE3":3857,"PHASE4":3859,"NA":3861},{"trials":3843,"activeCount":73},[],{"trials":3845,"activeCount":73},[],{"trials":3847,"activeCount":73},[3848],{"nctId":3849,"briefTitle":3850,"status":81,"phases":3851,"primaryCompletion":423,"completion":720,"start":664,"enrollment":3852,"conditions":3853,"interventions":3855},"NCT01611857","Phase I\u002FII Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach",[62,63],49,[3854,2032],"Malignant Solid Tumour",[3840,3856],"FOLFOX",{"trials":3858,"activeCount":73},[],{"trials":3860,"activeCount":73},[],{"trials":3862,"activeCount":73},[],{"intervention":3856,"totalTrials":139,"cells":3864},{"EARLY_PHASE1":3865,"PHASE1":3867,"PHASE2":3869,"PHASE3":3875,"PHASE4":3877,"NA":3879},{"trials":3866,"activeCount":73},[],{"trials":3868,"activeCount":73},[],{"trials":3870,"activeCount":73},[3871],{"nctId":3849,"briefTitle":3850,"status":81,"phases":3872,"primaryCompletion":423,"completion":720,"start":664,"enrollment":3852,"conditions":3873,"interventions":3874},[62,63],[3854,2032],[3840,3856],{"trials":3876,"activeCount":73},[],{"trials":3878,"activeCount":73},[],{"trials":3880,"activeCount":73},[],{"intervention":977,"totalTrials":139,"cells":3882},{"EARLY_PHASE1":3883,"PHASE1":3885,"PHASE2":3887,"PHASE3":3893,"PHASE4":3895,"NA":3897},{"trials":3884,"activeCount":73},[],{"trials":3886,"activeCount":73},[],{"trials":3888,"activeCount":73},[3889],{"nctId":970,"briefTitle":971,"status":81,"phases":3890,"primaryCompletion":561,"completion":956,"start":973,"enrollment":974,"conditions":3891,"interventions":3892},[63],[15],[90,784,977],{"trials":3894,"activeCount":73},[],{"trials":3896,"activeCount":73},[],{"trials":3898,"activeCount":73},[],{"intervention":1787,"totalTrials":139,"cells":3900},{"EARLY_PHASE1":3901,"PHASE1":3903,"PHASE2":3909,"PHASE3":3911,"PHASE4":3913,"NA":3915},{"trials":3902,"activeCount":73},[],{"trials":3904,"activeCount":73},[3905],{"nctId":1781,"briefTitle":1782,"status":81,"phases":3906,"primaryCompletion":1784,"completion":1784,"start":511,"enrollment":1489,"conditions":3907,"interventions":3908},[62],[29],[650,1787],{"trials":3910,"activeCount":73},[],{"trials":3912,"activeCount":73},[],{"trials":3914,"activeCount":73},[],{"trials":3916,"activeCount":73},[],{"intervention":3918,"totalTrials":139,"cells":3919},"PTK787\u002FZK222584 and Bevacizumab",{"EARLY_PHASE1":3920,"PHASE1":3922,"PHASE2":3932,"PHASE3":3934,"PHASE4":3936,"NA":3938},{"trials":3921,"activeCount":73},[],{"trials":3923,"activeCount":73},[3924],{"nctId":3925,"briefTitle":3926,"status":81,"phases":3927,"primaryCompletion":132,"completion":436,"start":569,"enrollment":657,"conditions":3928,"interventions":3931},"NCT00611793","PTK787\u002FZK222584 With Bevacizumab in Patients With Refractory and\u002For Advanced Malignancies",[62],[3929,3930],"Refractory Malignancy","Advanced Malignancies",[3918],{"trials":3933,"activeCount":73},[],{"trials":3935,"activeCount":73},[],{"trials":3937,"activeCount":73},[],{"trials":3939,"activeCount":73},[],{"intervention":2018,"totalTrials":139,"cells":3941},{"EARLY_PHASE1":3942,"PHASE1":3944,"PHASE2":3950,"PHASE3":3952,"PHASE4":3954,"NA":3956},{"trials":3943,"activeCount":73},[],{"trials":3945,"activeCount":73},[3946],{"nctId":2011,"briefTitle":2012,"status":1754,"phases":3947,"primaryCompletion":2014,"completion":2014,"start":1156,"enrollment":73,"conditions":3948,"interventions":3949},[62],[2016],[2018,990],{"trials":3951,"activeCount":73},[],{"trials":3953,"activeCount":73},[],{"trials":3955,"activeCount":73},[],{"trials":3957,"activeCount":73},[],{"intervention":3959,"totalTrials":139,"cells":3960},"BEZ235",{"EARLY_PHASE1":3961,"PHASE1":3963,"PHASE2":3974,"PHASE3":3976,"PHASE4":3978,"NA":3980},{"trials":3962,"activeCount":73},[],{"trials":3964,"activeCount":73},[3965],{"nctId":3966,"briefTitle":3967,"status":81,"phases":3968,"primaryCompletion":3969,"completion":3969,"start":3970,"enrollment":3971,"conditions":3972,"interventions":3973},"NCT01343498","Study of PI3 Kinase\u002FmTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors",[62],"2014-01","2011-04",33,[3854],[3959],{"trials":3975,"activeCount":73},[],{"trials":3977,"activeCount":73},[],{"trials":3979,"activeCount":73},[],{"trials":3981,"activeCount":73},[],{"intervention":3983,"totalTrials":139,"cells":3984},"LBH589, Paclitaxel, Carboplatin, Bevacizumab",{"EARLY_PHASE1":3985,"PHASE1":3987,"PHASE2":3996,"PHASE3":3998,"PHASE4":4000,"NA":4002},{"trials":3986,"activeCount":73},[],{"trials":3988,"activeCount":73},[3989],{"nctId":3990,"briefTitle":3991,"status":81,"phases":3992,"primaryCompletion":1022,"completion":1022,"start":694,"enrollment":595,"conditions":3993,"interventions":3995},"NCT00556088","LBH589, Paclitaxel, Carboplatin +\u002F- Bevacizumab for Solid Tumors",[62],[3994],"Solid Tumors",[3983],{"trials":3997,"activeCount":73},[],{"trials":3999,"activeCount":73},[],{"trials":4001,"activeCount":73},[],{"trials":4003,"activeCount":73},[],{"intervention":4005,"totalTrials":139,"cells":4006},"Capecitabine and Sorafenib",{"EARLY_PHASE1":4007,"PHASE1":4009,"PHASE2":4017,"PHASE3":4019,"PHASE4":4021,"NA":4023},{"trials":4008,"activeCount":73},[],{"trials":4010,"activeCount":73},[4011],{"nctId":4012,"briefTitle":4013,"status":81,"phases":4014,"primaryCompletion":956,"completion":1322,"start":581,"enrollment":859,"conditions":4015,"interventions":4016},"NCT00613145","Study of the Pharmacokinetics\u002FSafety of Sorafenib + Capecitabine in Advanced Solid Tumors",[62],[3929],[4005,4005],{"trials":4018,"activeCount":73},[],{"trials":4020,"activeCount":73},[],{"trials":4022,"activeCount":73},[],{"trials":4024,"activeCount":73},[],{"intervention":4026,"totalTrials":139,"cells":4027},"Imatinib and PTK\u002FZK222584",{"EARLY_PHASE1":4028,"PHASE1":4030,"PHASE2":4040,"PHASE3":4042,"PHASE4":4044,"NA":4046},{"trials":4029,"activeCount":73},[],{"trials":4031,"activeCount":73},[4032],{"nctId":4033,"briefTitle":4034,"status":81,"phases":4035,"primaryCompletion":132,"completion":3970,"start":4036,"enrollment":4037,"conditions":4038,"interventions":4039},"NCT00611689","Imatinib and PTK787\u002FZK222584 in Refractory and\u002For Advanced Solid Tumors",[62],"2004-07",45,[3929,3994],[4026],{"trials":4041,"activeCount":73},[],{"trials":4043,"activeCount":73},[],{"trials":4045,"activeCount":73},[],{"trials":4047,"activeCount":73},[],{"intervention":1604,"totalTrials":139,"cells":4049},{"EARLY_PHASE1":4050,"PHASE1":4052,"PHASE2":4058,"PHASE3":4060,"PHASE4":4062,"NA":4064},{"trials":4051,"activeCount":73},[],{"trials":4053,"activeCount":73},[4054],{"nctId":1595,"briefTitle":1596,"status":81,"phases":4055,"primaryCompletion":1598,"completion":1598,"start":552,"enrollment":1538,"conditions":4056,"interventions":4057},[62],[1600,135,1601,1602],[1604,102,1605],{"trials":4059,"activeCount":73},[],{"trials":4061,"activeCount":73},[],{"trials":4063,"activeCount":73},[],{"trials":4065,"activeCount":73},[],{"intervention":1249,"totalTrials":139,"cells":4067},{"EARLY_PHASE1":4068,"PHASE1":4070,"PHASE2":4076,"PHASE3":4078,"PHASE4":4080,"NA":4082},{"trials":4069,"activeCount":73},[],{"trials":4071,"activeCount":73},[4072],{"nctId":1237,"briefTitle":1238,"status":81,"phases":4073,"primaryCompletion":1240,"completion":1241,"start":1242,"enrollment":1243,"conditions":4074,"interventions":4075},[62],[1245,1246,33,1247],[1249,474],{"trials":4077,"activeCount":73},[],{"trials":4079,"activeCount":73},[],{"trials":4081,"activeCount":73},[],{"trials":4083,"activeCount":73},[],{"intervention":4085,"totalTrials":139,"cells":4086},"LBH589, Gemcitabine",{"EARLY_PHASE1":4087,"PHASE1":4089,"PHASE2":4097,"PHASE3":4099,"PHASE4":4101,"NA":4103},{"trials":4088,"activeCount":73},[],{"trials":4090,"activeCount":73},[4091],{"nctId":4092,"briefTitle":4093,"status":159,"phases":4094,"primaryCompletion":616,"completion":616,"start":946,"enrollment":760,"conditions":4095,"interventions":4096},"NCT00550199","LBH589 and Gemcitabine in the Treatment of Solid Tumors",[62],[3994],[4085],{"trials":4098,"activeCount":73},[],{"trials":4100,"activeCount":73},[],{"trials":4102,"activeCount":73},[],{"trials":4104,"activeCount":73},[],{"intervention":1912,"totalTrials":139,"cells":4106},{"EARLY_PHASE1":4107,"PHASE1":4109,"PHASE2":4115,"PHASE3":4117,"PHASE4":4119,"NA":4121},{"trials":4108,"activeCount":73},[],{"trials":4110,"activeCount":73},[4111],{"nctId":1905,"briefTitle":1906,"status":81,"phases":4112,"primaryCompletion":636,"completion":1303,"start":1908,"enrollment":947,"conditions":4113,"interventions":4114},[62],[1910],[853,1912],{"trials":4116,"activeCount":73},[],{"trials":4118,"activeCount":73},[],{"trials":4120,"activeCount":73},[],{"trials":4122,"activeCount":73},[],{"intervention":1795,"totalTrials":139,"cells":4124},{"EARLY_PHASE1":4125,"PHASE1":4127,"PHASE2":4133,"PHASE3":4135,"PHASE4":4137,"NA":4139},{"trials":4126,"activeCount":73},[],{"trials":4128,"activeCount":73},[4129],{"nctId":1789,"briefTitle":1790,"status":81,"phases":4130,"primaryCompletion":552,"completion":552,"start":1022,"enrollment":19,"conditions":4131,"interventions":4132},[62],[1793],[1795,650],{"trials":4134,"activeCount":73},[],{"trials":4136,"activeCount":73},[],{"trials":4138,"activeCount":73},[],{"trials":4140,"activeCount":73},[],{"intervention":1473,"totalTrials":139,"cells":4142},{"EARLY_PHASE1":4143,"PHASE1":4145,"PHASE2":4151,"PHASE3":4153,"PHASE4":4155,"NA":4157},{"trials":4144,"activeCount":73},[],{"trials":4146,"activeCount":73},[4147],{"nctId":1466,"briefTitle":1467,"status":159,"phases":4148,"primaryCompletion":1469,"completion":1469,"start":1470,"enrollment":399,"conditions":4149,"interventions":4150},[62],[531,165],[1473,415,1474],{"trials":4152,"activeCount":73},[],{"trials":4154,"activeCount":73},[],{"trials":4156,"activeCount":73},[],{"trials":4158,"activeCount":73},[],{"intervention":1474,"totalTrials":139,"cells":4160},{"EARLY_PHASE1":4161,"PHASE1":4163,"PHASE2":4169,"PHASE3":4171,"PHASE4":4173,"NA":4175},{"trials":4162,"activeCount":73},[],{"trials":4164,"activeCount":73},[4165],{"nctId":1466,"briefTitle":1467,"status":159,"phases":4166,"primaryCompletion":1469,"completion":1469,"start":1470,"enrollment":399,"conditions":4167,"interventions":4168},[62],[531,165],[1473,415,1474],{"trials":4170,"activeCount":73},[],{"trials":4172,"activeCount":73},[],{"trials":4174,"activeCount":73},[],{"trials":4176,"activeCount":73},[],{"intervention":440,"totalTrials":19,"cells":4178},{"EARLY_PHASE1":4179,"PHASE1":4181,"PHASE2":4183,"PHASE3":4241,"PHASE4":4255,"NA":4257},{"trials":4180,"activeCount":73},[],{"trials":4182,"activeCount":73},[],{"trials":4184,"activeCount":73},[4185,4189,4193,4197,4201,4205,4209,4213,4217,4221,4225,4229,4233,4237],{"nctId":1263,"briefTitle":1264,"status":81,"phases":4186,"primaryCompletion":730,"completion":1266,"start":1267,"enrollment":312,"conditions":4187,"interventions":4188},[63],[686],[485,630,440,631],{"nctId":432,"briefTitle":433,"status":81,"phases":4190,"primaryCompletion":435,"completion":436,"start":437,"enrollment":271,"conditions":4191,"interventions":4192},[63],[18],[440,398],{"nctId":453,"briefTitle":454,"status":81,"phases":4194,"primaryCompletion":456,"completion":457,"start":458,"enrollment":121,"conditions":4195,"interventions":4196},[63],[29],[440,461,398],{"nctId":497,"briefTitle":498,"status":81,"phases":4198,"primaryCompletion":500,"completion":500,"start":501,"enrollment":121,"conditions":4199,"interventions":4200},[63],[503],[440,398,505],{"nctId":1300,"briefTitle":1301,"status":81,"phases":4202,"primaryCompletion":1303,"completion":479,"start":1304,"enrollment":1305,"conditions":4203,"interventions":4204},[63],[23],[650,485,440,485,440],{"nctId":548,"briefTitle":549,"status":159,"phases":4206,"primaryCompletion":551,"completion":552,"start":553,"enrollment":9,"conditions":4207,"interventions":4208},[63],[26],[398,440,485],{"nctId":566,"briefTitle":567,"status":81,"phases":4210,"primaryCompletion":569,"completion":570,"start":571,"enrollment":572,"conditions":4211,"interventions":4212},[63],[574],[440,398,576],{"nctId":578,"briefTitle":579,"status":81,"phases":4214,"primaryCompletion":581,"completion":582,"start":583,"enrollment":312,"conditions":4215,"interventions":4216},[63],[585],[587,473,474,588],{"nctId":621,"briefTitle":622,"status":81,"phases":4218,"primaryCompletion":624,"completion":625,"start":457,"enrollment":626,"conditions":4219,"interventions":4220},[63],[628],[630,485,440,398,631],{"nctId":633,"briefTitle":634,"status":81,"phases":4222,"primaryCompletion":636,"completion":615,"start":481,"enrollment":637,"conditions":4223,"interventions":4224},[62,63],[15],[440,398,640],{"nctId":642,"briefTitle":643,"status":81,"phases":4226,"primaryCompletion":645,"completion":646,"start":616,"enrollment":425,"conditions":4227,"interventions":4228},[63],[648],[440,398,650],{"nctId":661,"briefTitle":662,"status":81,"phases":4230,"primaryCompletion":664,"completion":665,"start":666,"enrollment":667,"conditions":4231,"interventions":4232},[63],[165],[670,440,398],{"nctId":672,"briefTitle":673,"status":81,"phases":4234,"primaryCompletion":675,"completion":676,"start":677,"enrollment":657,"conditions":4235,"interventions":4236},[63],[679],[415,440,398],{"nctId":726,"briefTitle":727,"status":81,"phases":4238,"primaryCompletion":551,"completion":729,"start":730,"enrollment":731,"conditions":4239,"interventions":4240},[63],[733],[440,398,485,630],{"trials":4242,"activeCount":73},[4243,4247,4251],{"nctId":738,"briefTitle":739,"status":81,"phases":4244,"primaryCompletion":675,"completion":741,"start":742,"enrollment":572,"conditions":4245,"interventions":4246},[64],[18],[440,398,90,745],{"nctId":1153,"briefTitle":1154,"status":81,"phases":4248,"primaryCompletion":1156,"completion":96,"start":446,"enrollment":1157,"conditions":4249,"interventions":4250},[64],[15],[862,844,514,440],{"nctId":747,"briefTitle":748,"status":81,"phases":4252,"primaryCompletion":712,"completion":481,"start":750,"enrollment":751,"conditions":4253,"interventions":4254},[64],[753],[505,90,495,440,398],{"trials":4256,"activeCount":73},[],{"trials":4258,"activeCount":73},[4259],{"nctId":4260,"briefTitle":4261,"status":81,"phases":4262,"primaryCompletion":132,"completion":3970,"start":655,"enrollment":4037,"conditions":4263,"interventions":4264},"NCT00544167","Adjuvant Doxorubicin\u002FCyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer",[66],[15],[862,844,440,670],{"intervention":515,"totalTrials":12,"cells":4266},{"EARLY_PHASE1":4267,"PHASE1":4269,"PHASE2":4271,"PHASE3":4309,"PHASE4":4311,"NA":4313},{"trials":4268,"activeCount":73},[],{"trials":4270,"activeCount":73},[],{"trials":4272,"activeCount":73},[4273,4277,4281,4285,4289,4293,4297,4301,4305],{"nctId":2294,"briefTitle":2295,"status":81,"phases":4274,"primaryCompletion":2297,"completion":2297,"start":2298,"enrollment":2299,"conditions":4275,"interventions":4276},[63],[23],[843,515],{"nctId":507,"briefTitle":508,"status":81,"phases":4278,"primaryCompletion":510,"completion":511,"start":85,"enrollment":312,"conditions":4279,"interventions":4280},[63],[15],[514,515,398],{"nctId":1692,"briefTitle":1693,"status":81,"phases":4282,"primaryCompletion":561,"completion":1332,"start":656,"enrollment":16,"conditions":4283,"interventions":4284},[63],[15],[515,852],{"nctId":1363,"briefTitle":1364,"status":81,"phases":4286,"primaryCompletion":490,"completion":1366,"start":666,"enrollment":1367,"conditions":4287,"interventions":4288},[63],[15],[990,485,515],{"nctId":813,"briefTitle":814,"status":81,"phases":4290,"primaryCompletion":816,"completion":624,"start":817,"enrollment":312,"conditions":4291,"interventions":4292},[63],[15],[451,745,515],{"nctId":557,"briefTitle":558,"status":81,"phases":4294,"primaryCompletion":560,"completion":561,"start":435,"enrollment":562,"conditions":4295,"interventions":4296},[63],[15],[90,398,515],{"nctId":953,"briefTitle":954,"status":81,"phases":4298,"primaryCompletion":956,"completion":553,"start":957,"enrollment":958,"conditions":4299,"interventions":4300},[63],[15],[515,90],{"nctId":3828,"briefTitle":3829,"status":81,"phases":4302,"primaryCompletion":561,"completion":711,"start":490,"enrollment":1314,"conditions":4303,"interventions":4304},[63],[15],[3819,844,515],{"nctId":2274,"briefTitle":2275,"status":81,"phases":4306,"primaryCompletion":581,"completion":1908,"start":2264,"enrollment":859,"conditions":4307,"interventions":4308},[63],[1384,15],[2252,515],{"trials":4310,"activeCount":73},[],{"trials":4312,"activeCount":73},[],{"trials":4314,"activeCount":73},[4315],{"nctId":4316,"briefTitle":4317,"status":81,"phases":4318,"primaryCompletion":479,"completion":479,"start":945,"enrollment":4319,"conditions":4320,"interventions":4321},"NCT01048099","Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer",[66],283,[15],[515,1326],{"intervention":844,"totalTrials":1668,"cells":4323},{"EARLY_PHASE1":4324,"PHASE1":4326,"PHASE2":4328,"PHASE3":4350,"PHASE4":4360,"NA":4362},{"trials":4325,"activeCount":73},[],{"trials":4327,"activeCount":73},[],{"trials":4329,"activeCount":73},[4330,4334,4338,4342,4346],{"nctId":1620,"briefTitle":1621,"status":81,"phases":4331,"primaryCompletion":1623,"completion":616,"start":1624,"enrollment":1625,"conditions":4332,"interventions":4333},[63],[597],[844,1628,1629,1630,102],{"nctId":835,"briefTitle":836,"status":81,"phases":4335,"primaryCompletion":615,"completion":838,"start":84,"enrollment":839,"conditions":4336,"interventions":4337},[63],[841],[843,844,451],{"nctId":855,"briefTitle":856,"status":81,"phases":4339,"primaryCompletion":675,"completion":436,"start":858,"enrollment":859,"conditions":4340,"interventions":4341},[63],[15],[451,862,844],{"nctId":1144,"briefTitle":1145,"status":81,"phases":4343,"primaryCompletion":479,"completion":511,"start":605,"enrollment":1147,"conditions":4344,"interventions":4345},[63],[15],[514,844],{"nctId":3828,"briefTitle":3829,"status":81,"phases":4347,"primaryCompletion":561,"completion":711,"start":490,"enrollment":1314,"conditions":4348,"interventions":4349},[63],[15],[3819,844,515],{"trials":4351,"activeCount":73},[4352,4356],{"nctId":1153,"briefTitle":1154,"status":81,"phases":4353,"primaryCompletion":1156,"completion":96,"start":446,"enrollment":1157,"conditions":4354,"interventions":4355},[64],[15],[862,844,514,440],{"nctId":894,"briefTitle":895,"status":81,"phases":4357,"primaryCompletion":770,"completion":770,"start":897,"enrollment":898,"conditions":4358,"interventions":4359},[64],[15],[451,844,901,576],{"trials":4361,"activeCount":73},[],{"trials":4363,"activeCount":73},[4364],{"nctId":4260,"briefTitle":4261,"status":81,"phases":4365,"primaryCompletion":132,"completion":3970,"start":655,"enrollment":4037,"conditions":4366,"interventions":4367},[66],[15],[862,844,440,670],{"intervention":670,"totalTrials":1668,"cells":4369},{"EARLY_PHASE1":4370,"PHASE1":4372,"PHASE2":4378,"PHASE3":4404,"PHASE4":4406,"NA":4408},{"trials":4371,"activeCount":73},[],{"trials":4373,"activeCount":73},[4374],{"nctId":1535,"briefTitle":1536,"status":81,"phases":4375,"primaryCompletion":1353,"completion":1303,"start":561,"enrollment":1538,"conditions":4376,"interventions":4377},[62],[1540],[630,670],{"trials":4379,"activeCount":73},[4380,4384,4388,4392,4396,4400],{"nctId":2525,"briefTitle":2526,"status":81,"phases":4381,"primaryCompletion":97,"completion":1882,"start":466,"enrollment":2528,"conditions":4382,"interventions":4383},[63],[1245],[1407,670],{"nctId":1131,"briefTitle":1132,"status":81,"phases":4385,"primaryCompletion":1134,"completion":1135,"start":582,"enrollment":1136,"conditions":4386,"interventions":4387},[62,63],[23],[670,514],{"nctId":1561,"briefTitle":1562,"status":81,"phases":4389,"primaryCompletion":1266,"completion":1564,"start":780,"enrollment":111,"conditions":4390,"interventions":4391},[63],[26],[670,630],{"nctId":661,"briefTitle":662,"status":81,"phases":4393,"primaryCompletion":664,"completion":665,"start":666,"enrollment":667,"conditions":4394,"interventions":4395},[63],[165],[670,440,398],{"nctId":2428,"briefTitle":2429,"status":81,"phases":4397,"primaryCompletion":2431,"completion":2431,"start":1267,"enrollment":2432,"conditions":4398,"interventions":4399},[62,63],[1296],[670,1298],{"nctId":1879,"briefTitle":1880,"status":81,"phases":4401,"primaryCompletion":616,"completion":1882,"start":946,"enrollment":11,"conditions":4402,"interventions":4403},[62,63],[21],[103,670],{"trials":4405,"activeCount":73},[],{"trials":4407,"activeCount":73},[],{"trials":4409,"activeCount":73},[4410],{"nctId":4260,"briefTitle":4261,"status":81,"phases":4411,"primaryCompletion":132,"completion":3970,"start":655,"enrollment":4037,"conditions":4412,"interventions":4413},[66],[15],[862,844,440,670],{"intervention":862,"totalTrials":984,"cells":4415},{"EARLY_PHASE1":4416,"PHASE1":4418,"PHASE2":4420,"PHASE3":4426,"PHASE4":4432,"NA":4434},{"trials":4417,"activeCount":73},[],{"trials":4419,"activeCount":73},[],{"trials":4421,"activeCount":73},[4422],{"nctId":855,"briefTitle":856,"status":81,"phases":4423,"primaryCompletion":675,"completion":436,"start":858,"enrollment":859,"conditions":4424,"interventions":4425},[63],[15],[451,862,844],{"trials":4427,"activeCount":73},[4428],{"nctId":1153,"briefTitle":1154,"status":81,"phases":4429,"primaryCompletion":1156,"completion":96,"start":446,"enrollment":1157,"conditions":4430,"interventions":4431},[64],[15],[862,844,514,440],{"trials":4433,"activeCount":73},[],{"trials":4435,"activeCount":73},[4436],{"nctId":4260,"briefTitle":4261,"status":81,"phases":4437,"primaryCompletion":132,"completion":3970,"start":655,"enrollment":4037,"conditions":4438,"interventions":4439},[66],[15],[862,844,440,670],{"intervention":1326,"totalTrials":148,"cells":4441},{"EARLY_PHASE1":4442,"PHASE1":4444,"PHASE2":4446,"PHASE3":4452,"PHASE4":4454,"NA":4456},{"trials":4443,"activeCount":73},[],{"trials":4445,"activeCount":73},[],{"trials":4447,"activeCount":73},[4448],{"nctId":1319,"briefTitle":1320,"status":81,"phases":4449,"primaryCompletion":1032,"completion":720,"start":1322,"enrollment":1323,"conditions":4450,"interventions":4451},[63],[503],[485,1326,1327],{"trials":4453,"activeCount":73},[],{"trials":4455,"activeCount":73},[],{"trials":4457,"activeCount":73},[4458],{"nctId":4316,"briefTitle":4317,"status":81,"phases":4459,"primaryCompletion":479,"completion":479,"start":945,"enrollment":4319,"conditions":4460,"interventions":4461},[66],[15],[515,1326]]